Podcasts about clinical use

Welcome solo and group practice owners! We are Liath Dalton and Evan Dumas, your co-hosts of Group Practice Tech. In our latest episode, we share recent updates from Google Workspace that you may have questions about.  We discuss: The price changes to Google Workspace tiers Considerations for choosing the appropriate Google Workspace tier for your needs How client side encryption works using Google Gemini, Google's AI HIPAA appropriateness and ethical standards regarding AI use Communicating these standards to your team Cases where using AI would be appropriate  Google's updated appointment scheduler  Calendar sync as a contingency plan Listen here: https://personcenteredtech.com/group/podcast/ For more, visit our website. Resources Google Workspace Plan Tiers Google Workspace HIPAA Included Functionality (covered by BAA) Google Workspace HIPAA Implementation Guide About client-side encryption - Google Workspace Admin Help Learn about Gmail Client-side encryption - Gmail Help Generative AI in Google Workspace Privacy Hub Manage access to Gemini features in Workspace services PCT Resources Making Practice Life Easier and More Efficient With Google Workspace *Free* On-Demand seminar on utilizing Google Workspace to create more effective and secure systems includes PCT's Google Workspace Configuration Center & Checklist Relevant on-demand, legal-ethical CE training: The Evolving Legal-Ethical Standard of Care for the Clinical Use of Artificial Intelligence in Mental Health Gain insights into the benefits and challenges of incorporating AI technologies into their practice, understand the clinical implications, and learn how to navigate legal and ethical guidelines while maintaining compliance with HIPAA regulations. PCT's Comprehensive HIPAA Security Compliance Program (discounted) bundles: For Group Practices For Solo Practitioners PCT's HIPAA Risk Analysis & Risk Mitigation Planning service for mental health group practices -- care for your practice using our supportive, shame-free risk analysis and mitigation planning service. You'll have your Risk Analysis done within 2 hours, performed by a PCT consultant, using a tool built specifically for mental health group practice, and a mitigation checklist to help you reduce your risks. Group Practice Care Premium weekly (live & recorded) direct support & consultation service, Group Practice Office Hours -- including monthly session with therapist attorney Eric Ström, JD PhD LMHC + assignable staff HIPAA Security Awareness: Bring Your Own Device training + access to Device Security Center with step-by-step device-specific tutorials & registration forms for securing and documenting all personally owned & practice-provided devices (for *all* team members at no per-person cost) + assignable staff HIPAA Security Awareness: Remote Workspaces training for all team members + access to Remote Workspace Center with step-by-step tutorials & registration forms for securing and documenting Remote Workspaces (for *all* team members at no per-person cost) + more

Welcome solo and group practice owners! We are Liath Dalton and Evan Dumas, your co-hosts of Group Practice Tech. In our latest episode, we discuss the implications of the Section 1557 final rule on nondiscrimination for mental health practices.  We cover: The Section 1557 final rule, what it means, and when it takes effect How the Office of Civil Rights (OCR) disseminated this information Ways in which AI can be discriminatory What to consider when utilizing AI with patient care support tools as a mental health provider Listen here: https://personcenteredtech.com/group/podcast/ For more, visit our website. Resources The OCR/HHS "Dear Colleague Letter": Re: Ensuring Nondiscrimination Through the Use of Artificial Intelligence and Other Emerging Technologies OCR Notice: Ensuring Nondiscrimination in the Use of AI is Good Medicine HHS: HHS Artificial Intelligence Strategic Plan HHS: Artificial Intelligence Strategic Plan -- Slide Summary Federal Register: Section 1557 Final Rule PCT Resources Relevant on-demand, legal-ethical CE training: The Evolving Legal-Ethical Standard of Care for the Clinical Use of Artificial Intelligence in Mental Health Gain insights into the benefits and challenges of incorporating AI technologies into their practice, understand the clinical implications, and learn how to navigate legal and ethical guidelines while maintaining compliance with HIPAA regulations. PCT's Comprehensive HIPAA Security Compliance Program (discounted) bundles: For Group Practices For Solo Practitioners PCT's HIPAA Risk Analysis & Risk Mitigation Planning service for mental health group practices -- care for your practice using our supportive, shame-free risk analysis and mitigation planning service. You'll have your Risk Analysis done within 2 hours, performed by a PCT consultant, using a tool built specifically for mental health group practice, and a mitigation checklist to help you reduce your risks. Group Practice Care Premium weekly (live & recorded) direct support & consultation service, Group Practice Office Hours -- including monthly session with therapist attorney Eric Ström, JD PhD LMHC + assignable staff HIPAA Security Awareness: Bring Your Own Device training + access to Device Security Center with step-by-step device-specific tutorials & registration forms for securing and documenting all personally owned & practice-provided devices (for *all* team members at no per-person cost) + assignable staff HIPAA Security Awareness: Remote Workspaces training for all team members + access to Remote Workspace Center with step-by-step tutorials & registration forms for securing and documenting Remote Workspaces (for *all* team members at no per-person cost) + more

Welcome solo and group practice owners! We are Liath Dalton and Evan Dumas, your co-hosts of Group Practice Tech. In our latest episode, we share an overview of the big stories, developments, and regulatory changes that will impact group practices in 2025. We discuss: A proposed change to the HIPAA Security Rule, and how it will impact group practices OCR resuming their HIPAA Compliance Audit program Updates on telehealth provisions and exceptions for Medicare and important dates to know Updates on the Counseling Compact and the Social Work Licensure Compact Upcoming regulatory changes for AI use and our current recommendations Listen here: https://personcenteredtech.com/group/podcast/ For more, visit our website. Resources: Proposed New Rule From HHS: HIPAA Security Rule Notice of Proposed Rulemaking to Strengthen Cybersecurity for Electronic Protected Health Information Resumption of OCR's (the HIPAA Regulators) HIPAA Audit Program New Rule: HIPAA Privacy Rule Final Rule to Support Reproductive Health Care Privacy: Fact Sheet Model Attestation for a Requested Use or Disclosure of Protected Health Information Potentially Related to Reproductive Health Care New Rule: Fact Sheet 42 CFR Part 2 Final Rule Telehealth Update: DEA/HHS Temporary Rule, Medicare Coverage of Telehealth Services, and What to Watch For in 2025 Medicare Telehealth Flexibilities Get a Three-Month Lifeline JPM2025: Regulation of artificial intelligence: Navigating a new frontier in health care | JD Supra   PCT Resources: Relevant on-demand, legal-ethical CE training: Law & Ethics of Clinical Documentation for a post Roe world Addresses the practical applications of the US Supreme Court's ruling in Dobbs v. Jackson Women's Health Organization, with particular focus on the impacts this decision has on client confidentiality and documentation of clinical services Relevant on-demand, legal-ethical CE training: The Evolving Legal-Ethical Standard of Care for the Clinical Use of Artificial Intelligence in Mental Health Gain insights into the benefits and challenges of incorporating AI technologies into their practice, understand the clinical implications, and learn how to navigate legal and ethical guidelines while maintaining compliance with HIPAA regulations. PCT's Comprehensive HIPAA Security Compliance Program (discounted) bundles: For Group Practices For Solo Practitioners PCT's HIPAA Risk Analysis & Risk Mitigation Planning service for mental health group practices -- care for your practice using our supportive, shame-free risk analysis and mitigation planning service. You'll have your Risk Analysis done within 2 hours, performed by a PCT consultant, using a tool built specifically for mental health group practice, and a mitigation checklist to help you reduce your risks. Group Practice Care Premium weekly (live & recorded) direct support & consultation service, Group Practice Office Hours -- including monthly session with therapist attorney Eric Ström, JD PhD LMHC + assignable staff HIPAA Security Awareness: Bring Your Own Device training + access to Device Security Center with step-by-step device-specific tutorials & registration forms for securing and documenting all personally owned & practice-provided devices (for *all* team members at no per-person cost) + assignable staff HIPAA Security Awareness: Remote Workspaces training for all team members + access to Remote Workspace Center with step-by-step tutorials & registration forms for securing and documenting Remote Workspaces (for *all* team members at no per-person cost) + more

This week offers a double-feature of author interviews. First, please join author Gregg Stone as he discusses the article "Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial." Then, please join author Sung-Min Cho and our Circulation on the Run podcast host Greg Hundley as they discuss the article "Clinical Use of Bedside Portable Ultra-Low-Field Brain Magnetic Resonance Imaging in Patients on Extracorporeal Membrane Oxygenation: The Results From the Multicenter SAFE MRI ECMO Study." For the episode transcript, visit: https://www.ahajournals.org/do/10.1161/podcast.20241209.320025

Matthew A. Borgman, M.D. is a Professor of Pediatrics in the Division of Pediatric Critical Care at the University of Texas Southwestern.  Dr. Borgman graduated from Uniformed Services University (USU), he completed Pediatric Residency at Brooke Army Medical Center in 2007, followed by a fellowship in Critical Care at Boston Children's Hospital.  He is a prolific author in pediatric trauma management which has helped redefine the care of injured children. He is also the former national chair of the Pediatric Trauma Society Research Committee and has co-authored the 2022 Pediatric Traumatic Hemorrhagic Shock Consensus Conference Recommendations. Learning Objectives:By the end of this podcast, listeners should be able to:Define pediatric hemorrhagic shock and massive transfusion.Develop a guideline-based clinical approach to managing a child with hemorrhagic shock.Explore an expert's approach to managing a child with hemorrhagic shock where the evidence might not be clear. References:Russell et al. Pediatric traumatic hemorrhagic shock consensus conference recommendations. J Trauma Acute Care Surg. 2023 Jan 1;94(1S Suppl 1):S2-S10. Spinella et al. Transfusion Ratios and Deficits in Injured Children With Life-Threatening Bleeding. Pediatr Crit Care Med. 2022 Apr 1;23(4):235-244. Gaines et al. Low Titer Group O Whole Blood In Injured Children Requiring Massive Transfusion. Ann Surg. 2023 Apr 1;277(4):e919-e924. Moore et al. Fibrinolysis Shutdown in Trauma: Historical Review and Clinical Implications. Anesth Analg. 2019 Sep;129(3):762-773.Roberts et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013 Mar;17(10):1-79. Dewan et al. CRASH-3 - tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial. Trials. 2012 Jun 21;13:87.Spinella et al. Survey of transfusion policies at US and Canadian children's hospitals in 2008 and 2009. Transfusion. 2010 Nov;50(11):2328-35.Whitton TP, Healy WJ. Clinical Use and Interpretation of Thromboelastography. ATS Sch. 2023 Jan 9;4(1):96-97. MATIC-2: Questions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the showHow to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show. Thank you for listening to this episode of PedsCrit. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. Check out http://www.pedscrit.com for detailed show notes. And visit @critpeds on twitter and @pedscrit on instagram for real time show updates.

Happy Halloween, and welcome to another chilling episode of the NAVAS podcast, where we venture into the eerie depths of veterinary anesthesia! Join us as we lift the curtain on a topic that, while vital to advanced anesthesia practice, often sends shivers down the spine of even the bravest veterinary professionals—neuromuscular blocking agents (NMBAs) in veterinary patients. While paralytic agents play an important role in providing excellent quality muscle relaxation that can help facilitate a variety of procedures, their use often spooks even the seasoned anesthetist, as they can cause frightening problems if not used with great care. After listening to this episode, we hope you can avoid a jump scare anytime you need to use NMBA. Our guest for this spine-tingling episode is the highly esteemed Dr. Daniel Sakai from the University of Georgia College of Veterinary Medicine. Dr. Sakai, boarded veterinary anesthesiologist, has conducted extensive research on NMBAs, exploring their invaluable role in patient immobilization as well as how to optimize recovery from neuromuscular blockade. He's here to help us demystify these powerful agents, dissect their practical applications, and reveal how to use them safely and effectively to prevent any nightmarish outcomes for your patients. So, as the leaves fall and the shadows lengthen, grab a cozy blanket, tune in, and get ready to learn from one of the top minds in veterinary anesthesia. Just be warned—this episode might leave you spellbound!If you like what you hear, we have a couple of favors to ask of you:Become a member of NAVAS for access to more anesthesia and analgesia educational and RACE-approved CE content.Spread the word. Share our podcast on your socials or a discussion forum. That would really help us achieve our mission: Reduce mortality and morbidity in veterinary patients undergoing sedation, anesthesia, and analgesia through high-quality, peer-reviewed education. Thank you to our sponsor, Dechra - learn more about the pharmaceutical products Dechra has to offer veterinary professionals, such as Zenalpha.If you have questions about this episode or want to suggest topics for future episodes, reach out to the producers at education@mynavas.org.All opinions stated by the host and their guests are theirs alone and do not represent the thoughts or opinions of any corporation, university, or other business or governmental entity.

Welcome solo and group practice owners! We are Liath Dalton and Evan Dumas, your co-hosts of Group Practice Tech. In our latest episode, we look at Google's Gemini AI tool through a HIPAA lens.   We discuss: Common use cases for Gemini in a group practice context What's covered under the Google Workspace BAA (and what isn't) Ethical and legal considerations for using PHI with AI tools Informed consent for clients when AI tools are used for clinical documentation Establishing a Gemini usage policy for your practice Listen here: https://personcenteredtech.com/group/podcast/ For more, visit our website. Resources Google's Gemini AI for Google Workspace Google's HIPAA Included Functionality Google's HIPAA Implementation Guide (see Gemini section) PCT Resources CE courses: Using Artificial Intelligence (AI) as a Mental Health Clinician: Managing risk, ethics, and clinical benefits (2 legal-ethical CE credit hours) and/or The Evolving Legal-Ethical Standard of Care for the Clinical Use of Artificial Intelligence in Mental Health (1.5 legal-ethical CE credit hours) Group Practice Care Premium weekly (live & recorded) direct support & consultation service, Group Practice Office Hours -- including monthly session with therapist attorney Eric Ström, JD PhD LMHC + assignable staff HIPAA Security Awareness: Bring Your Own Device training + access to Device Security Center with step-by-step device-specific tutorials & registration forms for securing and documenting all personally owned & practice-provided devices (for *all* team members at no per-person cost) +  assignable staff HIPAA Security Awareness: Remote Workspaces training for all team members + access to Remote Workspace Center with step-by-step tutorials & registration forms for securing and documenting Remote Workspaces (for *all* team members at no per-person cost) + more HIPAA Risk Analysis & Risk Mitigation Planning service for mental health group practices -- care for your practice using our supportive, shame-free risk analysis and mitigation planning service. You'll have your Risk Analysis done within 2 hours, performed by a PCT consultant, using a tool built specifically for mental health group practice, and a mitigation checklist to help you reduce your risks.

It's a doozy this week - the origin and history of penicillin. It's so much more than just Alexander Fleming. From the ancient use of molds in bandages, to the arrival of germ theory, to World War II, Lynne will go into detail to describe the long and, at times, arduous process that ended with one of the most influential pharmaceutical products of all time.  Discovery of Penicillin International Historic Chemical Landmark  The Discovery of Penicillin - New Insights After More Than 75 Years of Clinical Use by Robert Gaynes History of Penicillin by Kholring Lalchhandama The real story behind penicillin by Dr. Howard Markel Alexander Fleming via Science History Institute  Moulds in Ancient and More Recent Medicine by Milton Wainwright Struggle Against Infection by W Fraser-Moodie Syphilis and Salvarsan by Gervase Vernon How a Deadly Fire Gave Birth to Modern Medicine by Linda Marsa Cocoanut Grove Fire via Wikipedia Fulton, penicillin and chance via Yale Medicine Magazine Please contact us with questions/concerns/comments at defunctdoctorspodcast@gmail.com. @defunctdoctorspodcast on Instagram, Facebook, X (Twitter), Threads, YouTube, and TikTok  Follow Lynne on Instagram @lynnedoodles555

Join Dr. Geo's interview with Dr. Ashley Ross, an esteemed associate professor in urology and clinical director at Northwestern Feinberg School of Medicine, they delve into personalized prostate cancer care. This discussion covers prostate biopsies, understanding clinical staging, and the critical role of prostate genomic tests in active surveillance. Discover modern tools like genomic tests, MRI, and PSA density, and how they inform treatment and surveillance decisions. The conversation also highlights patient engagement, lifestyle modifications, and the potential risks and benefits of surveillance strategies. Tune in for expert insights on navigating the complex landscape of prostate cancer diagnosis and treatment.----------------We are excited to introduce our July Sponsors:The Decipher Test: The Decipher Prostate Test by Veracyte analyzes specific genes in a prostate tumor to assess cancer aggressiveness, aiding in personalized treatment decisions and improving patient outcomes. Learn more about the Decipher Prostate Test here [https://bit.ly/4cNH805].ExoDx: The ExoDx Prostate Score is a non-invasive urine test for assessing the risk of aggressive prostate cancer, using cancer-specific genomic biomarkers. Scores below 15.6 indicate low risk, while scores above 15.6 indicate higher risk. Decisions on further actions, such as biopsies, should involve shared decision-making between the doctor and patient. Learn more about ExoDx here [https://bit.ly/3oA8rXC].XY Wellness: XY Wellness provides a high-value roadmap to health and wellness for men with prostate cancer. Co-founded by our Chief Medical Officer, they aim to help men thrive post-diagnosis. [Learn more about XY Wellness here [https://bit.ly/3uJPC7Z].----------------Thanks for listening to this week's episode. Subscribe to The Dr. Geo YouTube Channel to get more content like this and learn how you can live better with age.You can also listen to this episode and future episodes of the Dr. Geo Podcast by clicking HERE.----------------Follow Dr. Geo on social media. Facebook, Instagram Click here to become a member of Dr. Geo's Health Community.Improve your urological health with Dr. Geo's formulated supplement lines:XY Wellness for Prostate cancer lifestyle and nutrition: Mr. Happy Nutraceutical Supplements for prostate health and male optimal living.You can also check out Dr. Geo's online dispensary for other supplement recommendations Dr. Geo's Supplement Store____________________________________DISCLAIMER: This audio is educational and does not constitute medical advice. This audio's content is my opinion and not that of my employer(s) or any affiliated company.Use of this information is at your own risk. Geovanni Espinosa, N.D., will not assume any liability for any direct or indirect losses or damages that may result from the use of the information contained in this video, including but not limited to economic loss, injury, illness, or death.

The Actiwatch is a popular actigraphy device that is no longer sold or supported by Philips. Its discontinuation coincided with the launch of the AASM's “Act on Actigraphy” campaign, which highlights the importance of actigraphy testing for sleep disorders and urges payers to reimburse health care professionals for this medical service. Dr. Paul Raymond, vice chair of the AASM Coding and Reimbursement Advisory Committee, discusses reimbursement for actigraphy, its clinical use, and current and future options for device selection.

What You Will Learn: In the previous show, I provided a brief overview on how popular tea tree oil is, its versatile uses, and a potential regulation that could impact our access to it. Now, it's time to elaborate on its benefits and appealing characteristics. So, in this episode, I provide a general synthesis of tea tree oil's properties, history, and studies on its uses, safety, and applications. An introduction and review of the previous episode about tea tree oil (0 min) An overview of Melaleuca and tea tree oil including its family, species, and where it is endemic (1 min) The active component found in standardized tea tree oil that is antimicrobial and anti-inflammatory (3 min) A fun fact about how tea tree oil was named (3 min 30 sec) Historical uses of tea tree (4 min)  How tea tree oil was used during WWII by the Australians and why its use came out of favor (6 minutes) An overview of conditions that tea tree oil may benefit and why it is helpful (6 min 30 sec -9 min) Uses and applications of tea tree oil based on scientific studies and practical applications (9 min 30 sec) How essential oils affect the microbiome and how this relates to oral disinfectant rinses with them in it (16 min)  A natural, all-purpose cleaner recipe using tea tree oil (17 min) Using tea tree oil for mold in the environment and what diffusers NOT to use in moldy conditions (19 min 30 sec)  The emerging evidence for tea tree oil for psoriasis (20 min) Is tea tree oil effective against scabies and head lice? (21 min) A wrap up on the many properties of tea tree oil that make it so popular (23 min) Closing remarks (24 min) Resources From the Show:  Melaleuca (New World Encyclopedia, contains an overview and references) 14 Everyday Uses for Tea Tree Oil (Healthline, contains an overview and references to studies) Top Tea Tree Oil Uses and Benefits (Dr. Axe, contains links to studies discussed) Why I Still Love Tea Tree Oil but Am Very Happy to Meet the “Other” Melaleuca (ericifolia) Essential Oil on the Block  (My referenced Blog) Why Melaleuca ericifolia Essential Oil Deserves to Share the Spotlight with Tea Tree Oil (My referenced blog) Additional Resources on Tea Tree Oil Tea Tree Essential Oil Benefits: Fights Infections, Kills Mold & More! (Natural Living Family, Dr. Z) How Does Tea Tree Oil Help the Skin? (Healthline) What is Tea Tree essential oil used for? (Tisserand Aromatherapy) Tea Tree Oil as a Treatment for Oral Fungal Infection: New Research Alert (Tisserand Institute) Tea tree oil quality and constituents (Tisserand Institute) Soothing Seasonal Allergies Naturally with Essential Oils (The School for Aromatic Studies) Previous Episodes Mentioned on the Show: Ep. 418: The Many Wonders of Tea Tree Oil & The Backlash of Its Success Ep. 412: Five Cool Ways Essential Oils Can Holistically Support Hormone Health Ep. 408: 5 Important Things to Know About Essential Oils: Lessons Learned from Top Experts in Aromatherapy and Integrative Medicine Ep. 406: Natural Ways to Optimize Hormones and Sexual Health with Functional Medicine and Essential Oils Ep. 402 How Essential Oils Can Help You Heal from Mold-Related Illness Ep. 394: Essential Oils and the Microbiome, Do They Harm or Hurt Our Gut Bugs? Links to Learn More About My Offerings and Education on Essential Oils: My Essential Oils Community Membership My Resource Page My CEU Course for Practitioners on the Clinical Use of Essential Oils Learn more about your ad choices. Visit megaphone.fm/adchoices

What You Will Learn: In this episode, I discuss the importance of liver health. I explore how the liver affects overall health, its main functions, how it interacts with our hormones, gut, and thyroid, and how to promote liver health using lifestyle tools and essential oils. Here are some of the key points discussed during the show: Why the liver is so popular (1 min) The many physiological roles of the liver (3 min) The various functions of the liver (4 min) How hormones impact liver health (7 min)  How the liver regulates hormones (8 min) The liver-gut connection and why it is important (9.30 min) Why you need to have a clean colon before a liver cleanse (10 min) The role of the gut-liver link and estrobolome for estrogen balance in the body (11 min) The role of an enzyme in the gut that impacts estrogen clearance, hormone levels, and female health (12 min) The thyroid-liver link (13 min) Why integrative doctors will assess and support the liver and gut when hormones are imbalanced (15 min) Some key characteristics of essential oils that support liver and hormonal health (16 min) Some key symptoms indicating metabolic, female, and male hormonal imbalances (17.30 min) Tests for liver health and hormonal breakdown (19 min) The thyroid-cholesterol link (20 min) Ways to support a healthy liver (21 min) Why DIY cleaning with essential oils support a healthy liver (23 min) Foods to eat to nourish the liver (26 min) Nutrients that support liver health (27 min) Supplements that support a healthy liver (28 min) One of the healthiest things you can do for your brain and liver (28.5 min) Herb for liver conditions vs. liver health (29 min) Essential oils for liver health (30 min) Closing thoughts and showing gratitude (32 min) Resources From the Show: How Your Liver Affects Your Hormones and The Many Wonders of the Liver: Part I Supporting Your Liver for Better Hormone Balance: Part II The Gut-Liver Link and the Dangers of “Leaky Gut” Hepatoprotective Essential Oils: A Review Resources for Living a Healthy, Non-Toxic Life for Better Mind-Body Balance: Greener Living with Clean Food, Safe Cosmetics, Chemical-Free Household Products, and Quality Water  Previous Episodes Mentioned on the Show: Ep. 414: The Overlooked Vital Organ: Holistic Kidney Health with Dr. Jenna Henderson, ND Ep. 412: Five Cool Ways Essential Oils Can Holistically Support Hormone Health Ep. 394: Essential Oils and the Microbiome, Do They Harm or Hurt Our Gut Bugs? Links to Learn More About My Offerings and Education on Essential Oils: My Essential Oils Community Membership My Resource Page My CEU Course for Practitioners on the Clinical Use of Essential Oils Learn more about your ad choices. Visit megaphone.fm/adchoices

Reps. Greene, Massie to Trigger Motion to Vacate Vote House Passes Congressional Budget Office Data Sharing Act Senate Passes Minority Health Resolution, Considers Health Professional Shortages Senate Finance Leaders Release Proposal Aimed at Drug Shortages Ways and Means Expected to Markup Telehealth Legislation Sen. Klobuchar Requests Investigation into Health Data Analytics Firm United CEO Testifies on Change Healthcare Cyberattack Sen. Cassidy Urges White House to Detail Avian Flu Research Priorities FDA Releases Final LDT Rule FSMB Adopts Guidance on Clinical Use of AI Congressional Retirements and Resignations and more...

What You Will Learn: Frankincense essential oil is one of the most popular of all the essential oils to date. In fact, its multiple actions and its strong reputation for supporting wellness has earned it the nickname of the “King of Essential Oils.”  Yet, you've probably noticed that there are various types of frankincense essential oils. To confuse the consumer even more, many suppliers tout their version is best. So, how do you decide which one is right for you?  In this episode of the Essential Oil Revolution, we will explore some of the most popular frankincense (Boswellia) oils on the market. We will also discuss some basic actions and research about frankincense oil. This includes taking on the boswellic acid (BA) controversy! Here's an overview of what is discussed about Boswellia essential oils: The aromatic and spiritual properties associated with frankincense oil (2 min) The different frankincense species within their “Plant Family” (5 min) What causes variations in the constituents of frankincense species and why trusting your suppliers is important (6 min) The different types of frankincense species and their common countries of origin (7 min) The main compound that differentiates Boswellia sacra (B. sacra) from B. carterii (9 min) The wide-ranging benefits of B. serrata and B. frereana (12 min) How to choose which frankincense species may be best for you (13 min) Boswellic acids, are they in frankincense oils? (14 min) The sustainability of frankincense oil (19 min) The importance of varying our essential oils based on our body's changing needs and other factors (20 min) The bottom line on using frankincense essential oils (21 min) Additional resources (22 min) Referenced Blogs, Videos, and Information on Frankincense Oil: Decoding Frankincense Essential Oil Species: Your Go-To Solution to Alleviate Boswellia Oil Bafflement  Decoding Frankincense Essential Oil Species: Your Go-To Solution to Alleviate Boswellia Oil Bafflement Part II   The Take-Home Points on Choosing What Frankincense Oil to Use (Video, 2018)  What's All the Fuss About with Different Species of Frankincense Anyway  The Holy Oils of Frankincense (Species), Myrrh, and Spikenard (A brief overview) Additional Resources and Study Reviews on Frankincense Oil: Frankincense Essential Oil: Boswellia carterii (Aroma Web) Does Frankincense Oil Contain Boswellic Acid? (Tisserand Institute) Frankincense and Cancer (Tisserand Institute) Truth About Frankincense Oil Benefits for Cancer and Immunity (Natural Living Family, Dr. Z)  3 Frankincense Essential Oil Benefits: Healing for the Mind, Body, & Soul (Natural Living Family, Dr. Z.)  Management of basal cell carcinoma of the skin using frankincense (Boswellia sacra) essential oil: A case report ( June 2013, OA Alternative Medicine 1(2), DOI:10.13172/2052-7845-1-2-656, Full PDF) Essential Oils and Sustainability: Aroma Web: Guide to Essential Oils and Sustainability The International Union for Conservation of Nature (IUCN) maintains a helpful searchable database known as the IUCN Red List of Threatened Species. Links to Learn More About My Offerings and Education on Essential Oils: My Essential Oils Community Membership My Resource Page My CEU Course for Practitioners on the Clinical Use of Essential Oils Access My Essential Oil Free Resources, Additional Podcast Appearances, Articles, and Courses on Essential Oils Stay Connected! Sign-up for My Weekly Newsletter   Interested In a Naturopathic and Functional Medicine Consult? ·       I have a few spaces now for new clients! If You're in NY, Go Here. Want Suggestions on a Functional Medicine and Naturopathic Approach to Incorporating Essential Oils into Your Wellness Regime? ·        Go Here. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, we explore practical clinical tips for using broad-spectrum micronutrient supplements to treat mental health conditions. Can an individual's nutritional needs surpass population standards? Faculty: Amelia Villagomez, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Broad-Spectrum Micronutrients (BSMs) for Mental Health: What You Need to Know for Clinical Use Practical Tips for Using BSMs in the Clinical Practice

Drs. Jon McConathy, David A. Wolk, and Illya M. Nasrallah provide an update and information about neuro imaging related to Alzheimer's disease, particularly amyloid and tau imaging.

What You'll Learn: Since we are in the month of February, I thought it would be a good time to pause and focus on the heart. So, in this podcast I will provide a brief overview of cardiovascular health and how essential oils can support our healthy hearts. Note: Timestamps may shift with editing cuts, putting estimates here Why the heart gets so much attention as a topic in medicine in February (0 min) How heart disease is underrecognized in specific populations (4 min) How heart disease is viewed more often as a male disease (4.30 min) How breast cancer is more feared in women, yet heart disease causes more deaths in females (5 min) Typical risk factors for heart disease (6 min 50 sec) The great cholesterol debate, including what influences the effects of cholesterol on heart health (9 min 30 sec) Statins and heart disease (13.50 min) Unique symptoms in women related to an underlying heart problem (16 min) How hormones impact the heart (17 min) Isolation and socioeconomic factors as risk factors for heart disease (18 min) The impact of social connection on health health (19 min) How essential oils support heart health (21 min) Various heart risk factors that essential oils can help modulate (23 min) Some of my favorite single essential oils and blends that support heart health (24 min) The science of heart rate coherence, the HeartMath Institute, and mind-body medicine in reference to heart health (31 minute) The balancing impact of essential oils for the mind-body-heart (34 min)  Additional resources for essential oils education (35 min) Additional Blogs, Videos, and Information on Heart Health and Essential Oils: The Underrecognized, Number One Cause of Death in Women & What Conventional Cardiovascular Care is Missing for Healthy Hearts Hot Flashes, Depression, Digestive Issues, and Other Vague Symptoms… Is it Hormones or Heart Disease? The Most Important Thing Missing in Cardiovascular Care… For Women, Men, and Everyone Essential Oils for the Heart, Cardiovascular System, and Romance My Favorite Essential Oils for Mind-Body Heart Health Five Essential Oils and Blends for Holistic Heart Health & Cardiovascular Support Essential Oils to Support Heart Health and Enhance Connection Mind-Body-Heart Medicine: How Essential Oils Holistically Support Integrative Cardiovascular Health The Heart's Mysteries Explored and Why It May Be More Than a Pump: Integrative Medicine for Heart Health- Epigenetics, Essential Oils, and Beyond Links to Learn More About My Offerings and Education on Essential Oils: My Essential Oils Community Membership My Resource Page My CEU Course for Practitioners on the Clinical Use of Essential Oils Access My Essential Oil Free Resources, Additional Podcast Appearances, Articles, and Courses on Essential Oils Stay Connected! Sign-up for My Weekly Newsletter Essential Oil Blends to Support the Mind-Body-Heart Link (Not Treat Heart Disease!) Heart Oil Blend Heart Unifying Blend (One Heart) Stress Relief Blend (Stress Away) Previous Episodes Mentioned in the Show: Ep. 402 – Using Essential Oils to Heal from Mold-Related Illness with Dr. Jill Crista, ND Ep. 401 – Using Essential Oils for Headaches Ep. 397: Solosode Essential Oils for the Vagus Nerve Ep. 394: Essential Oils and the Microbiome, Do They Harm or Hurt our Gut Bugs? Learn more about your ad choices. Visit megaphone.fm/adchoices

In This Episode: In Silicon Valley, a hub of innovation, autism therapy faces critical challenges. One in 36 children in the U.S. is now diagnosed with autism spectrum disorder. Yet, technology's promise in therapy remains largely untapped. Only 35% of households with autistic children have access to Virtual Reality technology, contrasting with 72% in other families. Moreover, only 42% of these children receive technology-based interventions, with 23% personalized to their needs. Technology-Based Interventions Gaps in Silicon Valley Rising Autism Rates: 1 in 36 children in the United States has been identified with autism spectrum disorder (ASD) Accessibility and Cost: Only 35% of households with autistic children have access to virtual reality (VR) technology, compared to 72% of households without autistic children. Lack of Individualization: Only 42% of parents reported technology-based interventions for their autistic children, with just 23% tailored to specific needs. About Dr. Uli K. Chettipally: Dr. Uli K. Chettipally is an award-winning physician, researcher, and entrepreneur with over 20 years of experience in emergency medicine, clinical decision support, and digital therapeutics. He founded Sirica Therapeutics, which develops innovative autism therapy devices using robotics and virtual reality. As founder and president of InnovatorMD, the largest physician innovation platform, he fosters solutions for patient care, hosts events, and runs a Health Tech pre-seed accelerator. An author of publications and books like “Punish The Machine,” he's received awards for his innovations and actively serves on various boards dedicated to enhancing healthcare through technology. Show Notes: Inspiration Behind a Career in Healthcare Innovation: Dr. Uli shares his journey from practicing emergency medicine to facing the challenges of burnout and recurring problems in patient care. This led to an interest in leveraging technology and electronic health records to improve outcomes for both patients and healthcare providers.  The Role of Artificial Intelligence in Healthcare: Discussion on Dr. Uli's book, “Punish the Machine,” which explores the promise of AI in healthcare. The conversation covers how AI and technology can aid in clinical decision-making and improve healthcare delivery.  Impact of Digital Therapy on Patient Care: Insights into how predictive analytics and technology can customize treatments for individual patients, enhancing precision and reducing negative outcomes.  Adoption of Innovative Tools in Silicon Valley Medical Systems: Dr. Uli discusses the challenges and successes in implementing new technologies across hospitals, highlighting the systemic hurdles in healthcare business models.  Introducing Sirica's System: The inception of a community of physician innovators and the development of digital therapeutics, particularly for autism care, through a combination of robotics, virtual reality, and video gaming.  Broad Applications of VR and Robotics in Healthcare: Examination of how the technology initially aimed at stroke rehabilitation is applicable to a range of neurodevelopmental and neurodegenerative conditions.  Customizing Technology for Autism Spectrum Disorders: The process of tailoring the Syracus System to meet the diverse needs of individuals with autism, utilizing software to track progress and adapt treatment programs.  Home vs. Clinical Use of Therapeutic Technologies: Future prospects for making advanced therapeutic devices accessible in homes, enhancing convenience and regular use.  Measuring Effectiveness and Integrating Families into Treatment: Approaches to evaluating the impact of digital therapeutics on autism symptoms and the importance of involving family members in the treatment process.  Future of Emergency Medicine and Telehealth: Vision for a healthcare system that emphasizes prevention and continuous care, reducing the need for emergency services and hospitalization through the integration of technology and telehealth.

On this episode of the Essential Oil Revolution I discuss a very important, and even controversial topic in aromatherapy. It's regarding the answer to the question of “can you be allergic to essential oils?” Here's What You Will Learn: The three main reasons why “being allergic to essential oils” is controversial in aromatherapy Why it's important to have a balanced perspective on the literature and the information presented from various sources regarding the safety of essential oils The comparison between documented safety issues with medication errors and drug side effects vs. natural products What is an allergy? The four main types of allergies and what two classifications are associated with essential oils The terpene factor in relationship to contact dermatitis and how it relates to essential oil quality  The difference between photosensitization and contact dermatitis (type four hypersensitivity reactions) What to do if you have a reaction to essential oils, based on the Tisserand Institute's guidelines How to avoid skin sensitization reactions Resources My Blogs and Research Reviews on Essential Oils and Allergies: Allergic Response to Essential Oils? Part I (NaturalPath) Can Someone Have an Allergic Response to Essential Oils and What Would Make One “Allergic” to Begin With? Part II (NaturalPath) Essential Oils, Allergic Responses, and Skin Sensitization – Why and What You Should Know (Saratoga.com) Essential Oils, Allergic Responses, and Skin Sensitization – Why and What You Should Know Part 2  Additional Resources: Irritation and allergic reactions (Tisserand Institute) Digging Deeper into the Concept of Phototoxicity with Essential Oils  Contact Dermatitis to Essential Oils (Current Dermatology Reports) Essential Oil Diffusers and Asthma (AAAI) What You Need to Know About Allergic Reaction to Essential Oils (Healthline) What to Do If You Have an Adverse Reaction to Essential Oils (Tisserand Institute) Links to Learn More About My Offerings and Education on Essential Oils: My Essential Oils Community Membership My Resource Page My CEU Course for Practitioners on the Clinical Use of Essential Oils Learn more about your ad choices. Visit megaphone.fm/adchoices

What You Will Learn: How the aromatic and physical properties of essential oils can help to restore the body back to balance as they address symptoms.  The prevalence of headaches and what the most common symptoms are. The classification of headaches (primary, secondary, and cranial neuropathies). Common types of headaches and their symptoms (tension, migraine, and cluster). Common causes and triggers of headaches. These include low blood sugar from intermittent fasting, hormonal imbalances, gut issues, environmental exposures, nutrient deficiencies, and lifestyle factors. How to use the acronym “SNOOP” to determine if a headache is serious. Conventional and functional medicine laboratory blood work that can help determine the causes of headaches. Conventional treatments for headaches. Why we need to address the root cause of headaches. Some natural solutions for addressing headaches. Why peppermint and lavender were the essential oils I chose to review for headache relief. The concept of synergy and how it relates to essential oils. The two symptoms I use in my practice to indicate using peppermint oil may help a headache. The chemical makeup of peppermint oil and its various mechanisms of actions.  The meaning of amphoteric and how it relates to essential oils.  How peppermint oil can get to the root causes of headaches.  The three symptoms that co-occur with a headache that would lead me to select lavender oil for relief. The chemical makeup of lavender essential oil and its mechanism of actions. How lavender oil can address the root cause of headaches.  Studies that reported on the use of lavender oil for migraine headaches and prophylaxis.  How to use essential oils for headaches. Additional resources. If you like the show, you can help us out by subscribing and providing a rating, comment, and/or feedback on your favorite podcast player. This is a no-cost way to spread the word and ensures that we keep providing you with the best guests and essential oils education! Resources My Blogs, Videos, and Research Reviews on Headaches and Essential Oils: When Your Head Hurts: Headache Causes, Common Types, Red Flags That They are Serious, and Naturopathic and Functional Medicine Tests to Help Find the Cause My Aching Head! Naturopathic, Functional, and Mind-Body Medicine to Soothe Headaches Lavender Oil: The Go-To Essential Oil that Soothes the Brain, Lowers Anxious Symptoms, Calms Stress, Decreases Head Discomfort… and More! Peppermint Oil: A Powerful Ally for Digestive Health, Brain Support, Head Discomfort, and Much More Links to Learn More About My Offerings and Education on Essential Oils: My Essential Oils Community Membership My Resource Page My CEU Course for Practitioners on the Clinical Use of Essential Oils Previous Episode on the Vagus Nerve with Additional Resources: Ep. 397: Essential Oils for the Vagus Nerve Learn more about your ad choices. Visit megaphone.fm/adchoices

Learn what's to come in psychedelic therapy research including risk mitigation, contraindications, and treatment purposes as Andrew Penn explores this important subject.Episode SummaryIn this conversation, Andrew Penn, co-founder of the Organization of Psychedelic and Entheogenic Nurses (OPENurses), discusses the use of psychedelics in therapy and the challenges and concerns surrounding this emerging field. He addresses psychedelic misconceptions and hype, emphasizing the need for more research and caution. He also explores the potential benefits and risks of psychedelic retreats as well as the importance of psychedelic harm reduction. Penn highlights the specific considerations for using psychedelics in individuals with bipolar disorder and the need for further study in this area. Additionally, he discusses the potential impact of hormonal factors on psychedelic therapy and the recent approval of a treatment for postpartum depression. This conversation explores the manifestation of depression, contraindications for psychedelic use, serotonin syndrome, and the future of psychedelics.Discussed in this episode: The need for psychedelic therapy research to separate the hype from the realityHarm reduction strategies, such as safe spaces and support, in the use of psychedelicsRisks of bipolar disorder and psychedelics and the careful considerations to understandInteractions between psychedelics and hormones and the need for more researchThe recent approval of a treatment for postpartum depression in mental health careContraindications for psychedelic use, including a history of psychosis, cardiovascular disorders, and certain medicationsThe dangers of serotonin syndrome that can occur from the over-use of psychedelics The use of psychedelics in clinical vs. non-clinical settings "One myth to unpack is this idea that [psychedelic use] is ‘one and done' and ‘curative.' And frankly, I was part of that hype at the beginning, too, because in our very early studies, that's what we were starting to see." - Andrew PennRelated to this episode:Resources for Mental HealthListen to the series on Psychedelic-Assisted TherapyLearn more about the Organization of Psychedelic and Entheogenic NursesStay in touch with Andrew Penn on his website and LinkedIn.Check out Unseen Women in Psychedelic History by Maria ManginiIf you're passionate about advancing women's health, there are many ways you can support the Fempower Health Podcast. Here's how:Subscribe and Listen: Tune in to new episodes every Tuesday by subscribing to the Fempower Health Podcast on iTunes or Spotify or your favorite podcast platform. Your regular listenership is invaluable!Leave a Review:...

-- This podcast episode is sponsored by Fibion Inc. | The New Gold Standard for Sedentary Behaviour and Physical Activity Monitoring Learn more about Fibion: fibion.com/research https://sleepmeasurements.fibion.com --- Collect, store and manage SB and PA data easily and remotely - Discover new Fibion SENS Motion: https://web.fibion.com/sens

One can never pay too much attention to the vagus nerve. In fact, it's one of the hottest topics in wellness right now! This is because this tenth cranial nerve is critical in regulating many essential body functions, including of the heart, gut, brain, and lungs. We've touched upon the vagus nerve a few times with several amazing experts on the Essential Oils Revolution podcast! In this episode, I'm back for another solo episode in which I explore in more depth what some of my favorite essential oils are to support our vagus nerve. These essential oils were selected based on my clinical experience, their traditional use, and that they also have some evidence of favorably modulating our nervous system in scientific research.  What You Will Learn: The three parts of your autonomic nervous system and how they impact body physiology. The functions of the vagus nerve and how it can affect healing and restoration.  An overview of the multiple ways essential oils can calm the mind-body and support vagal tone. How essential oils influence our biochemistry and neurology to favorably benefit the vagus nerve. A review of the ways that lavender essential oil modulates the nervous system and vagal tone. What we can use to measure parasympathetic activity, including heart rate variability, which reflects vagal tone. Some of the issues with essential oil research.  An overview of the research on bergamot oil for calming the parasympathetic nervous system, which is mediated by the vagus nerve.  The studies on ylang ylang oil for positively influencing the vagal response.  If you should use an essential oil if you don't like the smell and how this relates to the nervous system.  Two honorable mentions of essential oils for regulating the vagus nerve response, petitgrain and fir oils. How volatile compounds from tree oils can mediate the negative effects of stress. A summary of how essential oils can optimize vagus nerve function and are applicable to the polyvagal theory. Have you used lavender oil, bergamot oil, ylang ylang, petitgrain, or fir oils to support your emotional health?  Share your feedback and comments on the website or your favorite podcast player! Please support the show by subscribing and providing a rating and feedback on your favorite podcast player. This is a no-cost way to spread the word and ensures we keep providing you with the best guests and essential oils education. Resources: My Blogs, Videos, and Research Reviews on the Vagus Nerve: What is the Vagus Nerve and Why is It So Popular Healing Trauma Through the Vagus Nerve: The Polyvagal Theory, the Nervous System, and Essential Oils Essential Oils, the Vagus Nerve, and the Polyvagal Theory My Three Favorite Essential Oils for the Vagus Nerve (+ 2 Honorable Mentions) which links to the studies reviewed Links to Learn More About My Offerings and Education on Essential Oils: My Essential Oils Community Membership My Resource Page My CEU Course for Practitioners on the Clinical Use of Essential Oils Previous Episodes with Expert Guest Who Highlighted the Vagus Nerve: Ep. 396: Calming the Parasympathetic Nervous System and Brain Support with Essential Oils with Jodi Cohen (link not up yet) Ep. 387: Using Essential Oils for Healthy, Thriving, Happy Kids with Integrative Pediatrician Dr. Elisa Song Ep. 386: The Polyvagal Theory, Calming the Limbic System, and Essential Oils with Dr. Thomas Moorcroft Ep. 298: Applied Neurology, The Vagus Nerve, and EOs with Dr. Kim Trager Ep. 281: Burgeoning Science & Bergamot with Dr. Danielle Daniel (interview with Samantha and referenced in this podcast) Learn more about your ad choices. Visit megaphone.fm/adchoices

In this podcast, Nirmish Shah, MD, discusses an overview, the results, and the preclinical and clinical impact of the study titled Preclinical and Clinical Use of AB1, a DNMT1 Protein Depleter, to Upregulate Fetal Hemoglobin in Townes Sickle Cell Disease (SCD) Mice and Patients with SCD. Dr Shah also presented on this topic at the American Society of Hematology's 2023 annual meeting in San Diego, CA.

Expert: Stefania Volpe, European Institute of Oncology Milan and University of Milan, Milan, Italy

You can find more key takeaways and resources specific to this episode on our dental page under the "Podcast Resources" drop down box. The podcast resources and other general resources that relate to infection control in dentistry can be found on our website; https://icap.nebraskamed.com/dental-facilities/ If you have specific infection control questions you would like to see on our podcast, please call our infection control hotline at 402.552.2881 or send us an email at nebraskaicap@nebraskamed.com. The Mouthy IP is now also on Twitter, follow us at @Mouthy_IP to chat with us about all things dental and infection control!

Drs Sumanta Pal and Laura Bukavina discuss the epidemiology of renal cell carcinoma, including risk factors, genetic screening, cystic disease, the microbiome, and the mycobiome. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984248). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Renal Cell Carcinoma https://emedicine.medscape.com/article/281340-overview Bladder Cancer https://emedicine.medscape.com/article/438262-overview Epidemiology of Renal Cell Carcinoma: 2022 Update https://pubmed.ncbi.nlm.nih.gov/36100483/ The Association Between BMI and Kidney Cancer Risk: An Updated Dose-response Meta-analysis in Accordance With PRISMA Guideline https://pubmed.ncbi.nlm.nih.gov/30383638/ Cigarette Smoking Is Associated With Advanced Renal Cell Carcinoma https://pubmed.ncbi.nlm.nih.gov/21502558/ Genetic Predisposition to Renal Cell Carcinoma: Implications for Counseling, Testing, Screening, and Management https://pubmed.ncbi.nlm.nih.gov/30372385/ von Hippel-Lindau Disease https://emedicine.medscape.com/article/1219430-overview Bosniak Classification of Cystic Renal Masses, Version 2019: A Pictorial Guide to Clinical Use https://pubmed.ncbi.nlm.nih.gov/34990332/ Sarcomatoid and Rhabdoid Renal Cell Carcinoma Pathology https://emedicine.medscape.com/article/1612066-overview The Role of Gut Microbiome in Immune Modulation in Metastatic Renal Cell Carcinoma https://pubmed.ncbi.nlm.nih.gov/36105887/ Human Gut Mycobiome and Fungal Community Interaction: The Unknown Musketeer in the Chemotherapy Response Status in Bladder Cancer https://pubmed.ncbi.nlm.nih.gov/36353067/ The Gut Microbiome and Metastatic Renal Cell Carcinoma https://pubmed.ncbi.nlm.nih.gov/36836036/ Sarcomatoid Chromophobe Renal Cell Carcinoma With Heterologous Component https://pubmed.ncbi.nlm.nih.gov/32095153/ Characteristics of Gut Microbiota in Patients With Clear Cell Renal Cell Carcinoma https://pubmed.ncbi.nlm.nih.gov/35865926/

Dr Jake Young joins Ethics Talk to discuss his article: “AMA Code of Medical Ethics' Opinions Related to Clinical Use of BMI.”  Recorded April 13, 2023.  Read the full article for free at JournalOfEthics.org

Welcome solo and group practice owners! We are Liath Dalton and Evan Dumas, your co-hosts of Group Practice Tech. In our latest episode, we're talking about AI use in a group practice setting. We discuss the ways that AI can impact group practices; risk analysis considerations; ways that AI is already utilized that you may not be aware of; setting explicit policies around AI; vetting whether AI services have access to PHI; steps to take when implementing HIPAA appropriate AI services; and our upcoming training with Eric Ström on navigating the legal and ethical guidelines of AI use for mental health practitioners.  Listen here: https://personcenteredtech.com/group/podcast/ For more, visit our website. PCT Resources:   PCT CE training: The Evolving Legal-Ethical Standard of Care for the Clinical Use of Artificial Intelligence in Mental Health Live on June 15th, On-Demand Self Study thereafter   Gain insights into the benefits and challenges of incorporating AI technologies into their practice, understand the clinical implications, and learn how to navigate legal and ethical guidelines while maintaining compliance with HIPAA regulations.   Presenter Eric Ström, JD PhD LMHC, brings a unique voice to the discourse around AI. He is an AMHCA ethics committee member, and the ethics advisor for the Washington Mental Health Counselors Association. Eric has taught a range of courses in counseling and professional ethics at a variety of graduate and undergraduate programs.   PCT On-Demand CE training: Modern Progress Notes: Considerations for Teletherapy, Insurance Audits, and Artificial Intelligence (AI) Modern documentation requires adaptivity and new strategies to manage things like electronic records, insurance audits, teletherapy sessions, and even artificial intelligence (AI). But what is ethical, safe and wise to implement in your practice? Join Dr. Maelisa McCaffrey (Hall) of QA Prep to address common considerations and learn new strategies for coping with notes in our modern era.   PCT's Group Practice Care Premium service with direct support & consultation service, Group Practice Office Hours, for group practice leaders plus: Assignable staff HIPAA Security Awareness: Remote Workspaces training for all team members Access to Remote Workspace Center with step-by-step tutorials & registration forms for securing documenting Remote Workspaces Assignable staff HIPAA Security Awareness: Bring Your Own Device training Access to Device Security Center with step-by-step device-specific tutorials & registration forms for securing documenting personal & practice-provided devices PCT's HIPAA Risk Analysis & Risk Mitigation Planning service for mental health group practices -- care for your practice using our supportive, shame-free risk analysis and mitigation planning service. You'll have your Risk Analysis done within 2 hours, performed by a PCT consultant, using a tool built specifically for mental health group practice, and a mitigation checklist to help you reduce your risks.   PCT's HIPAA Manual for Group Practices -- soon to include a Policy insert on the legal-ethical and appropriate utilization of AI in your mental health group practice.

How do you medically evaluate a person who presents with obesity? Drs Robert Kushner and Amanda Velazquez share practical tools and pearls for community clinicians. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982633). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Obesity Treatment & Management https://emedicine.medscape.com/article/123702-treatment A Primer on Smoking Cessation in Primary Care https://www.medscape.com/viewarticle/864524_3 Reasons for Underutilization of Bariatric Surgery: The Role of Insurance Benefit Design https://pubmed.ncbi.nlm.nih.gov/30425002/ Antiobesity Drug Therapy: An Individualized and Comprehensive Approach https://pubmed.ncbi.nlm.nih.gov/34341028/ Taking a Weight History – Using Mnemonics to Learn a Missing Skill in Medical Education [Version 1] https://mededpublish.org/articles/6-215 The Broadening Domain of the Metabolic Syndrome https://www.medscape.org/viewarticle/508282 Mallampati Classification https://emedicine.medscape.com/article/2172419-overview Acanthosis Nigricans https://emedicine.medscape.com/article/1102488-overview Cushing's Syndrome https://www.niddk.nih.gov/health-information/endocrine-diseases/cushings-syndrome Clinical Use of the Edmonton Obesity Staging System for the Assessment of Weight Management Outcomes in People With Class 3 Obesity https://pubmed.ncbi.nlm.nih.gov/35267942/ The Progression of Cardiometabolic Disease: Validation of a New Cardiometabolic Disease Staging System Applicable to Obesity https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3866217/ Modern Epigenetics Methods in Biological Research https://pubmed.ncbi.nlm.nih.gov/32645449/

In this panel episode recorded at SIR 2023, Drs. Stephen Hunt, Chuck Martin, and Gaurav Gadodia update us on current applications and future directions of augmented reality in interventional radiology. --- CHECK OUT OUR SPONSORS Medtronic Ellipsys Vascular Access System https://www.medtronic.com/ellipsys Reflow Medical https://www.reflowmedical.com/ --- EARN CME Reflect on how this Podcast applies to your day-to-day and earn free AMA PRA Category 1 CMEs: https://earnc.me/voyqG5 --- SHOW NOTES Dr. Hunt explains the differences between virtual reality (VR), augmented reality (AR), and mixed reality (MR) since there is increasing levels of overlap between virtual and real worlds with each category . He notes that all three are being explored in surgical fields, especially orthopedics and neurosurgery. Within IR, augmented reality can be used to adjust images and subtract out respiratory motion, making biopsies and ablations safer and more effective. Dr. Hunt became interested in AR when his PIGI Lab at the University of Pennsylvania needed 3D models to access liver tumors in experimental mice. Additionally, AR is a useful tool for planning difficult procedures and teaching interventional procedures to trainees across the globe. Dr. Martin speaks about the intersection of medicine and industry. He directs research studies for Mediview, a company focused on bringing AR into medical imaging. Dr. Martin speaks about the important role that industry plays in commercializing an invention and getting it into operators' hands. As larger companies enter the AR space, accessibility and user interfaces will improve. Additionally, the shift towards AR product development can guide future FDA regulations. Dr. Gadodia's engineering background made him excited to enter the AR space as resident at the Cleveland Clinic. He highlights applications of AR in the non-academic setting. Using a headset could increase procedural efficiency and access to care. Finally, we discuss major shifts in industry and medicine that favor the increasing use of AR, such as industry's need for clinician input in product development, the multitude of startups working on the same issues, and the overarching goal of patient safety. --- RESOURCES Ep. 7- Lung Tumor Ablation with Dr. Stephen Hunt: https://www.backtable.com/shows/vi/podcasts/7/lung-tumor-ablation Ep. 53- International IR Volunteer Work with Dr. Stephen Hunt: https://www.backtable.com/shows/vi/podcasts/53/international-ir-volunteer-work Mediview: https://mediview.com/ Microsoft HoloLens: https://www.microsoft.com/en-us/hololens Penn Image-Guided Interventions (PIGI) Lab: https://www.med.upenn.edu/pigilab/

What is “darkness deficiency,” and why is it important to the integrative practitioner? In this interview, sleep expert Catherine Darley, ND, discusses the clinical relevance of darkness deficiency and how it can lead to a melatonin imbalance. She then describes newer clinical uses of melatonin beyond sleep and talks in depth about melatonin efficacy, dosage, and safety. Darley is the founder of The Institute of Naturopathic Sleep Medicine and an internationally recognized expert on sleep disorders.   About the Expert Catherine Darley, ND, is the leader in natural sleep medicine. She combines her knowledge of sleep disorders with her training as a naturopathic physician to bridge these 2 fields. As a naturopath, her expertise lies in providing natural and effective treatments for sleep problems. She treats people of all ages and especially enjoys working with teens and their families. She founded The Institute of Naturopathic Sleep Medicine Inc in Seattle, which is dedicated to patient care, public education about sleep health, and consultation with high-risk populations such as first responders. Darley regularly writes articles and trains healthcare providers in the treatment of sleep disorders. She has served as adjunct faculty at Bastyr University and the National University of Natural Medicine.  

Erstmals konnte ein Alzheimer-Medikament in klinischen Studien eine Wirkung im Patienten zeigen. Was die Demenz-Forschung als Meilenstein feiert, ist von der Anwendung als Therapie allerdings noch ein gutes Stück entfernt. Noch immer ist die Krankheit nicht vollständig verstanden - und das, obwohl sie in einer alternden Gesellschaft immer sichtbarer wird. Wissenschaftsjournalistin Daniela Remus hat mit Demenzforschern über die Rolle von Proteinablagerungen im Gehirn und das Problem der späten Diagnose gesprochen. Im Gespräch mit Redakteurin Korinna Hennig erklärt sie, was es mit frühem Geruchsverlust auf sich hat, warum Bilder vom Gehirn schwierig zu interpretieren sind und wie es kommt, dass Frauen und Menschen aus einkommensschwache Gruppen ein höheres Risiko haben, an Demenz zu erkranken. DIE HINTERGRUNDINFORMATIONEN • Deutsches Zentrum für Neurodegenerative Erkrankungen https://www.dzne.de • Zentrum für Gedächtnisstörungen/Spezialambulanz an der Uniklinik in Köln | https://psychiatrie-psychotherapie.uk-koeln.de/klinik/ambulante-behandlung/spezialambulanz-gedaechtnisstoerungen/ • Gedächtnisambulanz Universitätsklinikum Eppendorf (UKE) in Hamburg | https://www.uke.de/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/behandlungsangebot/ambulante-angebote/index.html • Alzheimer Forschung Initiative | https://www.alzheimer-forschung.de • Studiendaten zum neuen Medikament Lecanemab | van Dyk Christopher H., Katayama, Sadayo M.D. et al: Lecanemab in Early Alzheimer's Disease. NEJM November 29, 2022: DOI: 10.1056/NEJMoa2212948 • Kritik an vermeintlichen Nebenwirkungen von Lecanemab | Piller C (2022): Second death linked to potential antibody treatment for Alzheimer's disease. Science. DOI: 10.1126/science.adf9701. • Suche nach genetischen Faktoren und Biomarkern, um Alzheimer Demenzen frühzeitig festzustellen - Forschung, an der Prof. Frank Jessen/Uniklinik Köln mitgearbeitet hat | Jansen, I. Gomez-Fonseca, D.et al: Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers. Acta neuropathologica.2022: 144(5): S. 821 - 842 [10.1007/s00401-022-02454-z] • Musikalische Aktivitäten schützen vor Gehirnabbau im Alter | Boettcher, A; Wirth, M. et al: Musical Activity During Life Is Associated With Multi-Domain Cognitive and Brain Benefits in Older Adults. Frontiers in psychology 2022, 13, 945709 [10.3389/fpsyg.2022.945709] • Zum klinischen Nutzen frühzeitiger Biomarker Identifikation bei Menschen mit geringen kognitiven Einschränkungen | Caprioglio, D; Consortium, E.A.D. The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer´s Disease Consortium Survey. Journal of Alzheimer's disease 2022, 89(2), S. 535 - 551 [10.3233/JAD-220333] • Zur Forschung, dass es offenbar Verbindungen gibt zwischen Psychosen und der Ausbildung von frontotemporalen Demenzen - Forschung, an der Dr. Holger Jahn/UKE in Hamburg und Ameos Klinikum in Heiligenhafen, mitgearbeitet hat | Koutsouleris, N.; Schroeter, M.et al: Exploring links between Psychosis and frontotemporal dementia using multimodal machine learning: Dementia Praecox Revisited. Jama Psychiatry, 2022, 79,9; S. 907-919 • Forschung zur "anderen" Eiweißablagerung neben den Amyloid Plaques | Benson, G; Frölich, L: Don´t forget about tau: The effect of APOE4 genotype on Alzheimer´s disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment-data from the dementia competence Network. Journal for Neural Transmission 2022, 129, 5-6, S. 477-486.

Erstmals konnte ein Alzheimer-Medikament in klinischen Studien eine Wirkung im Patienten zeigen. Was die Demenz-Forschung als Meilenstein feiert, ist von der Anwendung als Therapie allerdings noch ein gutes Stück entfernt. Noch immer ist die Krankheit nicht vollständig verstanden - und das, obwohl sie in einer alternden Gesellschaft immer sichtbarer wird. Wissenschaftsjournalistin Daniela Remus hat mit Demenzforschern über die Rolle von Proteinablagerungen im Gehirn und das Problem der späten Diagnose gesprochen. Im Gespräch mit Redakteurin Korinna Hennig erklärt sie, was es mit frühem Geruchsverlust auf sich hat, warum Bilder vom Gehirn schwierig zu interpretieren sind und wie es kommt, dass Frauen und Menschen aus einkommensschwache Gruppen ein höheres Risiko haben, an Demenz zu erkranken. DIE HINTERGRUNDINFORMATIONEN • Deutsches Zentrum für Neurodegenerative Erkrankungen https://www.dzne.de • Zentrum für Gedächtnisstörungen/Spezialambulanz an der Uniklinik in Köln | https://psychiatrie-psychotherapie.uk-koeln.de/klinik/ambulante-behandlung/spezialambulanz-gedaechtnisstoerungen/ • Gedächtnisambulanz Universitätsklinikum Eppendorf (UKE) in Hamburg | https://www.uke.de/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/behandlungsangebot/ambulante-angebote/index.html • Alzheimer Forschung Initiative | https://www.alzheimer-forschung.de • Studiendaten zum neuen Medikament Lecanemab | van Dyk Christopher H., Katayama, Sadayo M.D. et al: Lecanemab in Early Alzheimer's Disease. NEJM November 29, 2022: DOI: 10.1056/NEJMoa2212948 • Kritik an vermeintlichen Nebenwirkungen von Lecanemab | Piller C (2022): Second death linked to potential antibody treatment for Alzheimer's disease. Science. DOI: 10.1126/science.adf9701. • Suche nach genetischen Faktoren und Biomarkern, um Alzheimer Demenzen frühzeitig festzustellen - Forschung, an der Prof. Frank Jessen/Uniklinik Köln mitgearbeitet hat | Jansen, I. Gomez-Fonseca, D.et al: Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers. Acta neuropathologica.2022: 144(5): S. 821 - 842 [10.1007/s00401-022-02454-z] • Musikalische Aktivitäten schützen vor Gehirnabbau im Alter | Boettcher, A; Wirth, M. et al: Musical Activity During Life Is Associated With Multi-Domain Cognitive and Brain Benefits in Older Adults. Frontiers in psychology 2022, 13, 945709 [10.3389/fpsyg.2022.945709] • Zum klinischen Nutzen frühzeitiger Biomarker Identifikation bei Menschen mit geringen kognitiven Einschränkungen | Caprioglio, D; Consortium, E.A.D. The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer´s Disease Consortium Survey. Journal of Alzheimer's disease 2022, 89(2), S. 535 - 551 [10.3233/JAD-220333] • Zur Forschung, dass es offenbar Verbindungen gibt zwischen Psychosen und der Ausbildung von frontotemporalen Demenzen - Forschung, an der Dr. Holger Jahn/UKE in Hamburg und Ameos Klinikum in Heiligenhafen, mitgearbeitet hat | Koutsouleris, N.; Schroeter, M.et al: Exploring links between Psychosis and frontotemporal dementia using multimodal machine learning: Dementia Praecox Revisited. Jama Psychiatry, 2022, 79,9; S. 907-919 • Forschung zur "anderen" Eiweißablagerung neben den Amyloid Plaques | Benson, G; Frölich, L: Don´t forget about tau: The effect of APOE4 genotype on Alzheimer´s disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment-data from the dementia competence Network. Journal for Neural Transmission 2022, 129, 5-6, S. 477-486.

Why is measurement-based care so important to the overall treatment of schizophrenia? What are the most important reasons for using plasma antipsychotic levels when treating schizophrenia patients?   In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer about the importance of measuring plasma levels when administering antipsychotics.   With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on complex treatment-resistant psychotic disorders.  Episodes to be released under this theme include:  Part 1: Management of Complex Treatment-Resistant Psychotic Disorders with Dr. Michael Cummings  Part 2: The Clozapine Handbook with Dr. Jonathan Meyer  Part 3: Don't Guess! Measure: The Clinical Use of Antipsychotic Plasma Levels with Dr. Jonathan Meyer  Subscribe to the NEI Podcast, so that you don't miss another episode! 

--- This podcast episode is sponsored by Fibion Inc. | The New Gold Standard for Sedentary Behaviour and Physical Activity Monitoring Learn more about Fibion: fibion.com/research https://sleepmeasurements.fibion.com --- Collect, store and manage SB and PA data easily and remotely - Discover new Fibion SENS Motion: https://sens.fibion.com/

Dr. Kevin Nail joins Kevin and Alan again for more hot Acteon Piezotome Cube talk!  What is the best cookie? Intralift Kit Bone Surgery Kit Sinus Lift Kit

Huberman Lab Podcast Notes Key Takeaways Evolution of psychiatry: phase I – must be something genetic or how you were raised; phase II – must be a chemical imbalance or something chemically missingThere's actually a decrease in the level of activity in the brain on psychedelics, but the connectivity in regions increasesWe're all taught to retain some level of control in our day-to-day lives – part of the therapeutic effect of psychedelics is about untethering, letting go, and letting the system assume a natural state you've been fightingMental health disorders exist on a range; you may not reach a clinical level of OCD but you may have some tendencies or habits“If you can rid yourself of all to social and cultural constructions and re-examine these if we just discovered these today, we'd say that [psychedelics] are a huge breakthrough in psychiatry.” – Dr. Nolan WilliamsPsychedelics allow you to enter into a highly plastic state and reconsolidate memory which may drive a therapeutic effectAnti-psychotic therapeutic effects of cannabis are from the CBD and not the THC – the problem is we have potent strains now heavy with THC and low in CBDTranscranial magnetic stimulation (TMS) has the potential to send a signal to the prefrontal cortex and use the brain's own communication style to get it out of a depressive state – you're tapping into core circuitry with minimal side effects (unlike tinkering neurotransmitters)Read the full notes @ podcastnotes.orgIn this episode, my guest is Nolan Williams, M.D., a triple board-certified psychiatrist, neurologist and professor of psychiatry and behavioral sciences at Stanford School of Medicine. He is also the Director of the Stanford Brain Stimulation Lab. We discuss clinical applications for brain stimulation, behavioral protocols and novel drug treatments to halt and reverse mental health disorders, including depression and post-traumatic stress disorder (PTSD). We first discuss the neural circuits for self-identity and mood and stress control. We discuss Dr. Williams' work using transcranial magnetic stimulation (TMS) to depression, trauma, PTSD, and other mood disorders. We then dive deep into the history, biology, modern use, and safety margins of the various psychedelics, including MDMA, LSD, ketamine, ibogaine, ayahuasca, and psilocybin, as well as cannabis and the use of SSRIs in both adults and children. Finally, we discuss behavioral treatments for mental health disorders, including sleep and sleep deprivation, light exposure, exercise, and training to control the brain-heart-rate pathways. Regardless of age, all those interested in mental health should benefit from the incredible breadth and depth of Dr. Williams' knowledge and the clarity with which he conveys that information. Thank you to our sponsors AG1 (Athletic Greens): https://athleticgreens.com/huberman InsideTracker: https://insidetracker.com/huberman Eight Sleep: https://www.eightsleep.com/huberman ROKA: https://www.roka.com/huberman Supplements from Momentous https://www.livemomentous.com/huberman Huberman Lab Premium https://hubermanlab.com/premium For the full show notes, visit hubermanlab.com Timestamps (00:00:00) Dr. Nolan Williams, Brain Stimulation & Depression Treatment (00:03:31) Huberman Lab Premium (00:04:42) InsideTracker, Eight Sleep, ROKA (00:08:37) Momentous Supplements (00:09:16) Depression, Risk Factors, Emergency Psychiatric Treatments (00:15:11) The Brain-Heart Connection, Vagus Nerve, Prefrontal Cortex (00:17:51) Right vs. Left Brain Hemispheres & Mood Balance, Connectome (00:22:34) Heart Rate & Depression, Behavioral Interventions, Transcranial Magnetic Stimulation (TMS) (00:33:02) Prefrontal Cortex & Cognitive Control, TMS (00:37:46) AG1 (Athletic Greens) (00:39:00) Belief/Identity “Rules”, Re-scripting, TMS & Talk Therapy (00:45:49) Dorsolateral Prefrontal Cortex, TMS & Depression Treatment (00:48:36) Cingulate Cortex & Emotion, Dissociation & Catatonia (00:54:27) Ketamine, the Opioid System & Depression; Psychedelic Experience or Biology? (01:03:42) SSRIs, Serotonin & Depression; Childhood, Chemical Imbalance or Circuit? (01:13:58) Memories & “Rule” Creation; Psilocybin & “Rule” Resolution (01:21:00) MDMA & Post-Traumatic Stress Disorder (PTSD) Treatment, Psilocybin & Depression Treatment (01:24:12) Is MDMA Neurotoxic?, Drug Purity, Dopamine Surges, Post-MDMA Prolactin (01:30:38) Psilocybin, Brain Connectivity & Depression Treatment (01:34:53) Exposure Response Prevention: “Letting Go” & Depression Treatment (01:41:23) Normal Spectrums for Mental Health Disorders (01:45:35) Ibogaine & “Life Review”; PTSD, Depression & Clinical Trials (01:57:16) Clinical Use of Psychedelics (02:01:59) Ayahuasca, Brazilian Prisoner Study (02:06:55) Cannabis: THC, CBD & Psychosis, Clinical Uses (02:14:52) Personal Relative Drug Risk & Alcohol (02:20:42) Circadian Reset for Depression, Sleep Deprivation, Light (02:28:43) Stanford Neuromodulation Therapy (SNT) Study (02:34:25) Space Learning Theory & TMS Stimulation (02:45:35) Zero-Cost Support, YouTube Feedback, Spotify & Apple Reviews, Sponsors, Huberman Lab Premium, Neural Network Newsletter, Social Media Title Card Photo Credit: Mike Blabac Disclaimer

Huberman Lab: Read the notes at at podcastnotes.org. Don't forget to subscribe for free to our newsletter, the top 10 ideas of the week, every Monday --------- In this episode, my guest is Nolan Williams, M.D., a triple board-certified psychiatrist, neurologist and professor of psychiatry and behavioral sciences at Stanford School of Medicine. He is also the Director of the Stanford Brain Stimulation Lab. We discuss clinical applications for brain stimulation, behavioral protocols and novel drug treatments to halt and reverse mental health disorders, including depression and post-traumatic stress disorder (PTSD). We first discuss the neural circuits for self-identity and mood and stress control. We discuss Dr. Williams' work using transcranial magnetic stimulation (TMS) to depression, trauma, PTSD, and other mood disorders. We then dive deep into the history, biology, modern use, and safety margins of the various psychedelics, including MDMA, LSD, ketamine, ibogaine, ayahuasca, and psilocybin, as well as cannabis and the use of SSRIs in both adults and children. Finally, we discuss behavioral treatments for mental health disorders, including sleep and sleep deprivation, light exposure, exercise, and training to control the brain-heart-rate pathways. Regardless of age, all those interested in mental health should benefit from the incredible breadth and depth of Dr. Williams' knowledge and the clarity with which he conveys that information. Thank you to our sponsors AG1 (Athletic Greens): https://athleticgreens.com/huberman InsideTracker: https://insidetracker.com/huberman Eight Sleep: https://www.eightsleep.com/huberman ROKA: https://www.roka.com/huberman Supplements from Momentous https://www.livemomentous.com/huberman Huberman Lab Premium https://hubermanlab.com/premium For the full show notes, visit hubermanlab.com Timestamps (00:00:00) Dr. Nolan Williams, Brain Stimulation & Depression Treatment (00:03:31) Huberman Lab Premium (00:04:42) InsideTracker, Eight Sleep, ROKA (00:08:37) Momentous Supplements (00:09:16) Depression, Risk Factors, Emergency Psychiatric Treatments (00:15:11) The Brain-Heart Connection, Vagus Nerve, Prefrontal Cortex (00:17:51) Right vs. Left Brain Hemispheres & Mood Balance, Connectome (00:22:34) Heart Rate & Depression, Behavioral Interventions, Transcranial Magnetic Stimulation (TMS) (00:33:02) Prefrontal Cortex & Cognitive Control, TMS (00:37:46) AG1 (Athletic Greens) (00:39:00) Belief/Identity “Rules”, Re-scripting, TMS & Talk Therapy (00:45:49) Dorsolateral Prefrontal Cortex, TMS & Depression Treatment (00:48:36) Cingulate Cortex & Emotion, Dissociation & Catatonia (00:54:27) Ketamine, the Opioid System & Depression; Psychedelic Experience or Biology? (01:03:42) SSRIs, Serotonin & Depression; Childhood, Chemical Imbalance or Circuit? (01:13:58) Memories & “Rule” Creation; Psilocybin & “Rule” Resolution (01:21:00) MDMA & Post-Traumatic Stress Disorder (PTSD) Treatment, Psilocybin & Depression Treatment (01:24:12) Is MDMA Neurotoxic?, Drug Purity, Dopamine Surges, Post-MDMA Prolactin (01:30:38) Psilocybin, Brain Connectivity & Depression Treatment (01:34:53) Exposure Response Prevention: “Letting Go” & Depression Treatment (01:41:23) Normal Spectrums for Mental Health Disorders (01:45:35) Ibogaine & “Life Review”; PTSD, Depression & Clinical Trials (01:57:16) Clinical Use of Psychedelics (02:01:59) Ayahuasca, Brazilian Prisoner Study (02:06:55) Cannabis: THC, CBD & Psychosis, Clinical Uses (02:14:52) Personal Relative Drug Risk & Alcohol (02:20:42) Circadian Reset for Depression, Sleep Deprivation, Light (02:28:43) Stanford Neuromodulation Therapy (SNT) Study (02:34:25) Space Learning Theory & TMS Stimulation (02:45:35) Zero-Cost Support, YouTube Feedback, Spotify & Apple Reviews, Sponsors, Huberman Lab Premium, Neural Network Newsletter, Social Media Title Card Photo Credit: Mike Blabac Disclaimer

In this episode, my guest is Nolan Williams, M.D., a triple board-certified psychiatrist, neurologist and professor of psychiatry and behavioral sciences at Stanford School of Medicine. He is also the Director of the Stanford Brain Stimulation Lab. We discuss clinical applications for brain stimulation, behavioral protocols and novel drug treatments to halt and reverse mental health disorders, including depression and post-traumatic stress disorder (PTSD). We first discuss the neural circuits for self-identity and mood and stress control. We discuss Dr. Williams' work using transcranial magnetic stimulation (TMS) to depression, trauma, PTSD, and other mood disorders. We then dive deep into the history, biology, modern use, and safety margins of the various psychedelics, including MDMA, LSD, ketamine, ibogaine, ayahuasca, and psilocybin, as well as cannabis and the use of SSRIs in both adults and children. Finally, we discuss behavioral treatments for mental health disorders, including sleep and sleep deprivation, light exposure, exercise, and training to control the brain-heart-rate pathways. Regardless of age, all those interested in mental health should benefit from the incredible breadth and depth of Dr. Williams' knowledge and the clarity with which he conveys that information. Thank you to our sponsors AG1 (Athletic Greens): https://athleticgreens.com/huberman InsideTracker: https://insidetracker.com/huberman Eight Sleep: https://www.eightsleep.com/huberman ROKA: https://www.roka.com/huberman Supplements from Momentous https://www.livemomentous.com/huberman Huberman Lab Premium https://hubermanlab.com/premium For the full show notes, visit hubermanlab.com Timestamps (00:00:00) Dr. Nolan Williams, Brain Stimulation & Depression Treatment (00:03:31) Huberman Lab Premium (00:04:42) InsideTracker, Eight Sleep, ROKA (00:08:37) Momentous Supplements (00:09:16) Depression, Risk Factors, Emergency Psychiatric Treatments (00:15:11) The Brain-Heart Connection, Vagus Nerve, Prefrontal Cortex (00:17:51) Right vs. Left Brain Hemispheres & Mood Balance, Connectome (00:22:34) Heart Rate & Depression, Behavioral Interventions, Transcranial Magnetic Stimulation (TMS) (00:33:02) Prefrontal Cortex & Cognitive Control, TMS (00:37:46) AG1 (Athletic Greens) (00:39:00) Belief/Identity “Rules”, Re-scripting, TMS & Talk Therapy (00:45:49) Dorsolateral Prefrontal Cortex, TMS & Depression Treatment (00:48:36) Cingulate Cortex & Emotion, Dissociation & Catatonia (00:54:27) Ketamine, the Opioid System & Depression; Psychedelic Experience or Biology? (01:03:42) SSRIs, Serotonin & Depression; Childhood, Chemical Imbalance or Circuit? (01:13:58) Memories & “Rule” Creation; Psilocybin & “Rule” Resolution (01:21:00) MDMA & Post-Traumatic Stress Disorder (PTSD) Treatment, Psilocybin & Depression Treatment (01:24:12) Is MDMA Neurotoxic?, Drug Purity, Dopamine Surges, Post-MDMA Prolactin (01:30:38) Psilocybin, Brain Connectivity & Depression Treatment (01:34:53) Exposure Response Prevention: “Letting Go” & Depression Treatment (01:41:23) Normal Spectrums for Mental Health Disorders (01:45:35) Ibogaine & “Life Review”; PTSD, Depression & Clinical Trials (01:57:16) Clinical Use of Psychedelics (02:01:59) Ayahuasca, Brazilian Prisoner Study (02:06:55) Cannabis: THC, CBD & Psychosis, Clinical Uses (02:14:52) Personal Relative Drug Risk & Alcohol (02:20:42) Circadian Reset for Depression, Sleep Deprivation, Light (02:28:43) Stanford Neuromodulation Therapy (SNT) Study (02:34:25) Space Learning Theory & TMS Stimulation (02:45:35) Zero-Cost Support, YouTube Feedback, Spotify & Apple Reviews, Sponsors, Huberman Lab Premium, Neural Network Newsletter, Social Media Title Card Photo Credit: Mike Blabac Disclaimer

Drs John Kane and Jonathan M. Meyer discuss what new antipsychotic drugs are available for schizophrenia. What drugs are under development? And what do they potentially offer? Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969528). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources The Clozapine Handbook: Stahl's Handbooks (Stahl's Essential Psychopharmacology Handbooks) New Edition https://www.amazon.com/Clozapine-Handbook-Handbooks-Essential-Psychopharmacology/dp/1108447465 The Clinical Use of Antipsychotic Plasma Levels: Stahl's Handbooks (Stahl's Essential Psychopharmacology Handbooks) Kindle Edition https://www.amazon.com/Clinical-Antipsychotic-Plasma-Levels-Psychopharmacology-ebook-dp-B09B3VMM8N/dp/B09B3VMM8N Clinical Use of Reserpine in Psychiatry: Comparison With Chlorpromazine https://nyaspubs.onlinelibrary.wiley.com/doi/epdf/10.1111/j.1749-6632.1955.tb42463.x Arvid Carlsson https://www.nobelprize.org/prizes/medicine/2000/carlsson/facts/ Clozapine: Guidelines for Clinical Management https://pubmed.ncbi.nlm.nih.gov/2670914/ Clozapine: Medscape Drugs & Diseases https://reference.medscape.com/drug/clozaril-versacloz-clozapine-342972 Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-analysis https://www.psychiatrist.com/jcp/movement-disorder/tardive-dyskinesia-prevalence/ Efficacy and Safety of Lumateperone for Treatment of Schizophrenia — A Randomized Clinical Trial https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2758022 Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities https://pubs.acs.org/doi/10.1021/acsptsci.2c00016 Trace Amine-Associated Receptor 1 Modulates Dopaminergic Activity https://jpet.aspetjournals.org/content/324/3/948.long A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia https://www.nejm.org/doi/10.1056/NEJMoa1911772 A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia https://clinicaltrials.gov/ct2/show/NCT04109950 A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms https://clinicaltrials.gov/ct2/show/NCT03669640 Emerging Schizophrenia Drugs Target Negative Symptoms https://www.medscape.com/viewarticle/953336 Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2008.06091591 Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia https://www.nejm.org/doi/10.1056/NEJMoa2017015 Risperidone, 2 mg/day vs. 4 mg/day, in First-Episode, Acutely Psychotic Patients: Treatment Efficacy and Effects on Fine Motor Functioning https://www.psychiatrist.com/jcp/schizophrenia/risperidone-mgday-vs-mgday-episode-acutely-psychotic/

The development of penicillin started – but definitely did not end – with the chance discovery of some mold in a petri dish. There is so much more to the story. Research: Bernard, Diane. “How a miracle drug changed the fight against infection during World War II.” Washington Post. 7/11/2020. https://www.washingtonpost.com/history/2020/07/11/penicillin-coronavirus-florey-wwii-infection/ British Library. “Inventor(s) of the month, Alexander Fleming and the story of Penicillin.” 7/28/2021. https://blogs.bl.uk/business/2021/07/inventors-of-the-month-alexander-fleming.html Chain, E. et al. “Penicillin as a Chemotherapeutic Agent.” The Lancet. Vol. 236, Issue 6104. 8/24/1940. https://doi.org/10.1016/S0140-6736(01)08728-1 Fleming A. On the Antibacterial Action of Cultures of a Penicillium, with Special Reference to their Use in the Isolation of B. influenzæ. Br J Exp Pathol. 1929 Jun;10(3):226–36. PMCID: PMC2048009. Gaynes, Robert. “The Discovery of Penicillin—New Insights After More Than 75 Years of Clinical Use.” Emerg Infect Dis. 2017 May; 23(5): 849–853.. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403050/ Lee, Victoria. “Microbial Transformations.” Historical Studies in the Natural Sciences, SEPTEMBER 2018, Vol. 48, No. 4. Via JSTOR. https://www.jstor.org/stable/10.2307/26507225 National Museums of Scotland. “Culture Vessel.” https://www.nms.ac.uk/explore-our-collections/stories/science-and-technology/culture-vessel/ Quinn, Roswell. “Rethinking Antibiotic Research and Development: World War II and the Penicillin Collaborative.” American Journal of Public Health | March 2013, Vol 103, No. 3. Scibilia, Anthony Julius. “Being Prometheus in 1943:: Bringing Penicillin to the Working Man.” Pennsylvania History: A Journal of Mid-Atlantic Studies , Vol. 80, No. 3 (Summer 2013). https://www.jstor.org/stable/10.5325/pennhistory.80.3.0442 Science History. “Alexander Fleming.” 12/5/2017. https://www.sciencehistory.org/historical-profile/alexander-fleming Science Museum. “How Was Penicillin Developed?” 2/23/2021. https://www.sciencemuseum.org.uk/objects-and-stories/how-was-penicillin-developed Shama, Gilbert. “'Déjà Vu' – The Recycling of Penicillin in Post-liberation Paris.” Pharmacy in History , 2013, Vol. 55, No. 1 (2013). Via JSTOR. https://www.jstor.org/stable/23645718 The Alexander Fleming Laboratory Museum, London, UK. “The Discovery and Development of Penicillin 1928-1945.” 11/19/1999. https://www.acs.org/content/dam/acsorg/education/whatischemistry/landmarks/flemingpenicillin/the-discovery-and-development-of-penicillin-commemorative-booklet.pdf Wainwright, Milton. “Moulds in Folk Medicine.” Folklore , 1989, Vol. 100, No. 2 (1989). https://www.jstor.org/stable/1260294 Wainwright, Milton. “The History of the Therapeutic Use of Crude Penicillin.” Medical History, 1987, 31: 41-50. Williams KJ. The introduction of 'chemotherapy' using arsphenamine - the first magic bullet. J R Soc Med. 2009 Aug;102(8):343-8. doi: 10.1258/jrsm.2009.09k036. PMID: 19679737; PMCID: PMC2726818. Wood, Jonathan. “Penicillin: The Oxford Story.” Oxford News Blog. 7/16/2010. https://www.ox.ac.uk/news/science-blog/penicillin-oxford-story Zaffiri, Lorenzo et al. “History of Antibiotics. From Salvarsan to Cephalosporins.” Journal of Investigative Surgery, 25, 67–77, 2012.  See omnystudio.com/listener for privacy information.

--- This podcast episode is sponsored by Fibion Inc. | The New Gold Standard for Sedentary Behaviour and Physical Activity Monitoring Learn more about Fibion: fibion.com/research https://sleepmeasurements.fibion.com --- Collect, store and manage SB and PA data easily and remotely - Discover new Fibion SENS Motion: https://sens.fibion.com/

Editor-in-Chief, Robert Amdur, MD, reviews two papers that explain how to improve OAR sparing based on more demanding dosimetry goals. One article is published in the March/April issue of PRO titled “Clinical Use of A Priori Knowledge of OAR Sparing During Radiotherapy Treatment for Oropharyngeal Cancer: Dosimetric and Patient Reported Outcome Improvements”. The other article is In Press at PRO and titled “Stricter Postoperative Oropharyngeal Cancer Radiotherapy Normal Tissue Dose Constraints Are Feasible”.

In this episode of the Emoroid Digest Podcast we sit down with our guest Dr. Prakash Gyawali and discuss the ACG Clinical Guidelines on the Clinical Use of Esophageal Physiologic Testing. Dr. Prakash Gyawali is an academic gastroenterologist at Washington University School of Medicine, St. Louis. He is a Professor of Medicine, Director of the Neurogastroenterology and Motility Program, and Program Director of the Gastroenterology Fellowship Training program at Washington University in St. Louis.  His academic interests include esophageal motility, gastroesophageal reflux disease, and functional disorders. He is involved in motility testing using high-resolution manometry, esophageal ambulatory pH and impedance monitoring, wireless pH monitoring, and endoscopic functional lumen imaging probe (FLIP). He is actively involved in clinical research involving neurogastroenterology and motility, and has published over 250 original articles, invited reviews and book chapters.   ACG Guideline: https://journals.lww.com/ajg/fulltext/2020/09000/acg_clinical_guidelines__clinical_use_of.19.aspx   Lyon's Criteria: https://gut.bmj.com/content/67/7/1351   Host: Dr. Chuma Obineme (GI Fellow) –  https://twitter.com/TypicallySilent    Co-Host: Dr. Jason Brown - https://med.emory.edu/directory/profile/?u=JMBROW2    Visual Abstract Link -  https://twitter.com/EmoryGastroHep/status/1485454303850549250?s=20&t=c0giwII7dGO3Xco7grv2tQ   Link to the Emoroid Digest Website - https://med.emory.edu/departments/medicine/divisions/digestive-diseases/education/emoroid-digest.html 

Resources: MT&B Episode #8- “Authenticity in Music Part 2”MT&B Episode #37 - “Heavy Metal in Music Therapy”

Dr. Elroy Vojdani discusses the Clinical Uses of Immune System Testing with Dr. Ben Weitz.  You might consider this a follow up podcast to the presentation by Dr. Aristo Vojdani in episode 244 where he explained the new immune system test that he developed for Cyrex Labs called the Lymphocyte Map test.   [If you enjoy […]

Les dernières lignes directrices canadiennes sur la dyslipidémie ont été publiées en 2021. Quelles en sont les nouveautés et les faits saillants ? Que doit-on retenir de ces recommandations pour le dépistage, la prévention et le traitement ? On en discute avec Michel Germain, détenteur de la certification américaine de Board Certified Cardiology Pharmacist et pharmacien à l'Institut universitaire de cardiologie et de pneumologie de Québec. RÉFÉRENCES Lignes directrices canadiennes 2021 sur la dyslipidémie https://www.onlinecjc.ca/article/S0828-282X(21)00165-3/fulltext Tableau de calcul du score de Framingham de la Société canadienne de cardiologie https://ccs.ca/app/uploads/2020/12/FRS_eng_2017_fnl_greyscale.pdf Outil d'aide à la décision | Prévention des maladies cardiovasculaire http://calculatricercv.inesss.qc.ca/ Rosenson R.S. et coll. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability. Cardiovasc Drugs Ther. 2017; 31(2): 179–186. DOI: 10.1007/s10557-017-6723-4 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427100/ Alberti K. et coll. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006 May;23(5):469-80. DOI : 10.1111/j.1464-5491.2006.01858.x https://pubmed.ncbi.nlm.nih.gov/16681555/

Maurizio Corbetta is Full Professor and Chair of Neurology in the Department of Neuroscience at the University of Padua, Italy. He is also the founding director of the new Padua Neuroscience Center, a highly interdisciplinary research programme centered on the idea of brain networks in health and society. After receiving is M.D. from the University of Pavia in Italy, he carried out a residency in Neurology at the University of Verona. In 1990 he moved to US, carting out a fellowship in NeuroImaging at Barnes Hospital at Wash U in St. Louis. While in St. Louis, he worked his way up to being the Norman J. Strupp Professor of Neurology, and Professor of Radiology, Anatomy, Neurobiology Bioengineering and Neuroscience at Wash University, as well as Director of Stroke and Brain Injury Rehabilitation at the Rehabilitation Institute of St. Louis. He moved back to Italy, to teh University of Padua, in 2016. Prof. Corbetta has pioneered experiments on the neural mechanisms of human attention using Positron Emission Tomography (PET). He has discovered two brain networks dedicated to attention control, the dorsal and ventral attention networks, and developed a brain model of attention. His clinical work has focused on the physiological correlates of focal injury. He has developed a pathogenetic model of the syndrome of hemispatial neglect. He is currently developing novel methods for studying the functional organization of the brain using functional connectivity MRI, magneto-encephalography (MEG), and electro-corticography (EcoG). He is also working on the effects of focal injuries on the network organization of brain systems with an eye to neuromodulation. He is known for the high level of rigor and deep insight of his research, and has over 16 papers with over 1000 citations. Discussion In our conversation, we discuss some of the key people that influenced him, the incredible team of people at Washington University, as well as some of his early work. We also discuss his perspective on the utility and information in resting state fMRI. He's senior author of one of the most provocative and compelling explanations for resting state activity that I've seen: titled The secret life of predictive brains: what's spontaneous activity for? Pezzulo et al TICS 2021. We go on from there to discuss his perspective of the substantial importance and profound potential of systems level neuroimaging to not only basic neuroscience but also to clinical practice. Toward the end of our discussion, he highlights how diagnosis and treatment of stroke with neuromodulation can leverage current state of the art neuroimaging techniques.

Welcome back to Chat Sh*t Get Fit - Chatting Supplements. This week we explore something that's been around for some time and is often referred to as "magic gold" especially in regards to inflammation. Question is - is this all marketing or does the latest science back up its many claims? We focus on two "designer products" in Zooki - a turmeric sachet and The Turmeric Co - a turmeric shot. They both boast big claims with the latter even having a page dedicated to science. We naturally dive in and dissect the page. The things we focus on in particular are Inflammation DOMs Gut Inflammation Cholesterol Levels - Blood Lipids Skin Health Sports Performance & Physical Exercise We then finish by taking a quick look at probiotics and gut health (a fairly new field if we're being honest) and see if those magic yoghurts you see in the supermarket (looking at you Activia) are worth the price tag! Of course, as with all in this series, it's important you consult your doctor first before supplementing anything into your diet.   Fancy joining us on Patreon? We are super excited about this as it allows you to get more great content from us but at the same time support the running of the podcast. Currently, we have 3 tiers with extras ranging from access to live podcast specials and Monthly Q&As  all the way to Train Primal Membership & health-boosting consultation calls with Bill or Tom. For all the details and to join us on Patreon head to patreon.com/csgfpodcast   Cannonball Coffee. Great tasting and super powerful which WILL give you a boost in the gym. We spoke to Cannonball Coffee on a previous podcast and you can listen to that here to see why we are such fans. So if you want to support us in some small way and get some great coffee head to cannonballcoffee.co.uk and use code PRIMAL10 for 10% off any order.   New to the show? Head back to episode 1 "Let's Chat, Covid & Fitness" where we give an introduction into who we are and talk about the current state of ourselves and the fitness industry during this covid pandemic.   Find us on Instagram @bill_trainprimal @coachtomreardon   Website: www.chatshitgetfit.com Email: csgfpodcast@gmail.com   Studies Mentioned Joint Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials Take turmeric with a grain of salt Curcumin supplementation likely attenuates delayed onset muscle soreness (DOMS) Effects of turmeric extract supplementation on inflammation and muscle damage after a half-marathon race Oral turmeric/curcumin effects on inflammatory markers in chronic inflammatory diseases The effect of curcumin on the brain-gut axis in rat model of irritable bowel syndrome Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors A Systematic Review and Meta-analysis of Randomized Controlled Trials on the Effects of Turmeric and Curcuminoids on Blood Lipids in Adults with Metabolic Diseases A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS) Effects of Turmeric and Curcumin Dietary Supplementation on Human Gut Microbiota Effects of turmeric on uremic pruritus in end-stage renal disease patients Use of Curcumin in Psoriasis Anti-inflammatory effects of oral supplementation with curcumin Effects of Turmeric (Curcuma longa) on Skin Health: A Systematic Review of the Clinical Evidence Potential of Curcumin in Skin Disorders Effects of curcumin supplementation on sport and physical exercise: a systematic review The effect of Curcumin/Turmeric on blood pressure modulation Effects of probiotic supplementation on anthropometric and metabolic characteristics in adults with metabolic syndrome Supplementation of Probiotics and Its Effects on Physically Active Individuals and Athletes  

Featuring perspectives from Dr Jeremy Abramson and Ms Elizabeth Zerante, including the following topics:  Introduction (0:00) Toxicities with Chimeric Antigen Receptor (CAR) T-Cell Therapy — Grading, Management and Patient Education (10:56) Case: A woman in her early 60s with relapsed/refractory chronic lymphocytic leukemia (CLL) (36:28) Case: A woman in her early 60s with relapsed/refractory CLL/SLL (small lymphocytic lymphoma) (40:46) Case: A man in his early 80s with a history of CLL and double-hit diffuse large B-cell lymphoma (45:15) Clinical Use of CAR T-Cell Therapies for CLL and Lymphomas (55:25) CME information and select publications

This is an incredible opportunity to sit with a legend in the field of attachment research! Dr. Carol George worked directly with Mary Main, and her dissertation lead to the Adult Attachment Inventory (AAI). She and Sue Marriott discuss wide-ranging topics all with the eye on using the whole of this research in real life and in the clinical setting. Learn about the Adult Attachment Projective, the history of the research and more about this incredible woman who is a living legend.

Go online to PeerView.com/DJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What's new in the treatment of small cell lung cancer (SCLC), and how can healthcare professionals make the most of the accelerating therapeutic progress to maximize benefits for patients? For many years, SCLC was viewed as a challenging subtype of lung cancer, with limited treatment advances and poor outcomes, but recent developments have brought new options and hope for improved outcomes for these patients. This educational activity provides a grand tour through the exciting changes in the treatment arsenal for SCLC, including the impact of chemo-immunotherapy in the first-line setting and the emergence of the transcription inhibitor lurbinectedin as the new standard of care in the second-line setting, as well as a sneak peek into the future, focusing on what's looking promising on the horizon based on findings from ongoing research efforts. The exploration of the treatment advances are framed by cases to illustrate how to integrate the new therapeutic options into practice and what factors to consider when constructing individualized treatment plans. Progress is inconsequential if it doesn't rapidly translate into practice. Are you prepared to take all the necessary steps to improve outcomes for your patients with SCLC? Upon completion of this activity, participants should be better able to: Review the role and rationale for integrating novel therapies into the SCLC treatment arsenal, Assess the safety and efficacy data evaluating established and newly approved treatment options, including transcription inhibition as a novel therapeutic approach, for patients with SCLC, Integrate approved and emerging therapies into individualized management plans for patients with SCLC taking into consideration the latest findings, current guidelines and recommendations, and patient needs and preferences.

Go online to PeerView.com/DJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What's new in the treatment of small cell lung cancer (SCLC), and how can healthcare professionals make the most of the accelerating therapeutic progress to maximize benefits for patients? For many years, SCLC was viewed as a challenging subtype of lung cancer, with limited treatment advances and poor outcomes, but recent developments have brought new options and hope for improved outcomes for these patients. This educational activity provides a grand tour through the exciting changes in the treatment arsenal for SCLC, including the impact of chemo-immunotherapy in the first-line setting and the emergence of the transcription inhibitor lurbinectedin as the new standard of care in the second-line setting, as well as a sneak peek into the future, focusing on what's looking promising on the horizon based on findings from ongoing research efforts. The exploration of the treatment advances are framed by cases to illustrate how to integrate the new therapeutic options into practice and what factors to consider when constructing individualized treatment plans. Progress is inconsequential if it doesn't rapidly translate into practice. Are you prepared to take all the necessary steps to improve outcomes for your patients with SCLC? Upon completion of this activity, participants should be better able to: Review the role and rationale for integrating novel therapies into the SCLC treatment arsenal, Assess the safety and efficacy data evaluating established and newly approved treatment options, including transcription inhibition as a novel therapeutic approach, for patients with SCLC, Integrate approved and emerging therapies into individualized management plans for patients with SCLC taking into consideration the latest findings, current guidelines and recommendations, and patient needs and preferences.

Go online to PeerView.com/DJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What's new in the treatment of small cell lung cancer (SCLC), and how can healthcare professionals make the most of the accelerating therapeutic progress to maximize benefits for patients? For many years, SCLC was viewed as a challenging subtype of lung cancer, with limited treatment advances and poor outcomes, but recent developments have brought new options and hope for improved outcomes for these patients. This educational activity provides a grand tour through the exciting changes in the treatment arsenal for SCLC, including the impact of chemo-immunotherapy in the first-line setting and the emergence of the transcription inhibitor lurbinectedin as the new standard of care in the second-line setting, as well as a sneak peek into the future, focusing on what's looking promising on the horizon based on findings from ongoing research efforts. The exploration of the treatment advances are framed by cases to illustrate how to integrate the new therapeutic options into practice and what factors to consider when constructing individualized treatment plans. Progress is inconsequential if it doesn't rapidly translate into practice. Are you prepared to take all the necessary steps to improve outcomes for your patients with SCLC? Upon completion of this activity, participants should be better able to: Review the role and rationale for integrating novel therapies into the SCLC treatment arsenal, Assess the safety and efficacy data evaluating established and newly approved treatment options, including transcription inhibition as a novel therapeutic approach, for patients with SCLC, Integrate approved and emerging therapies into individualized management plans for patients with SCLC taking into consideration the latest findings, current guidelines and recommendations, and patient needs and preferences.

Go online to PeerView.com/DJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What's new in the treatment of small cell lung cancer (SCLC), and how can healthcare professionals make the most of the accelerating therapeutic progress to maximize benefits for patients? For many years, SCLC was viewed as a challenging subtype of lung cancer, with limited treatment advances and poor outcomes, but recent developments have brought new options and hope for improved outcomes for these patients. This educational activity provides a grand tour through the exciting changes in the treatment arsenal for SCLC, including the impact of chemo-immunotherapy in the first-line setting and the emergence of the transcription inhibitor lurbinectedin as the new standard of care in the second-line setting, as well as a sneak peek into the future, focusing on what's looking promising on the horizon based on findings from ongoing research efforts. The exploration of the treatment advances are framed by cases to illustrate how to integrate the new therapeutic options into practice and what factors to consider when constructing individualized treatment plans. Progress is inconsequential if it doesn't rapidly translate into practice. Are you prepared to take all the necessary steps to improve outcomes for your patients with SCLC? Upon completion of this activity, participants should be better able to: Review the role and rationale for integrating novel therapies into the SCLC treatment arsenal, Assess the safety and efficacy data evaluating established and newly approved treatment options, including transcription inhibition as a novel therapeutic approach, for patients with SCLC, Integrate approved and emerging therapies into individualized management plans for patients with SCLC taking into consideration the latest findings, current guidelines and recommendations, and patient needs and preferences.

Go online to PeerView.com/DJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What's new in the treatment of small cell lung cancer (SCLC), and how can healthcare professionals make the most of the accelerating therapeutic progress to maximize benefits for patients? For many years, SCLC was viewed as a challenging subtype of lung cancer, with limited treatment advances and poor outcomes, but recent developments have brought new options and hope for improved outcomes for these patients. This educational activity provides a grand tour through the exciting changes in the treatment arsenal for SCLC, including the impact of chemo-immunotherapy in the first-line setting and the emergence of the transcription inhibitor lurbinectedin as the new standard of care in the second-line setting, as well as a sneak peek into the future, focusing on what's looking promising on the horizon based on findings from ongoing research efforts. The exploration of the treatment advances are framed by cases to illustrate how to integrate the new therapeutic options into practice and what factors to consider when constructing individualized treatment plans. Progress is inconsequential if it doesn't rapidly translate into practice. Are you prepared to take all the necessary steps to improve outcomes for your patients with SCLC? Upon completion of this activity, participants should be better able to: Review the role and rationale for integrating novel therapies into the SCLC treatment arsenal, Assess the safety and efficacy data evaluating established and newly approved treatment options, including transcription inhibition as a novel therapeutic approach, for patients with SCLC, Integrate approved and emerging therapies into individualized management plans for patients with SCLC taking into consideration the latest findings, current guidelines and recommendations, and patient needs and preferences.

Go online to PeerView.com/DJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What's new in the treatment of small cell lung cancer (SCLC), and how can healthcare professionals make the most of the accelerating therapeutic progress to maximize benefits for patients? For many years, SCLC was viewed as a challenging subtype of lung cancer, with limited treatment advances and poor outcomes, but recent developments have brought new options and hope for improved outcomes for these patients. This educational activity provides a grand tour through the exciting changes in the treatment arsenal for SCLC, including the impact of chemo-immunotherapy in the first-line setting and the emergence of the transcription inhibitor lurbinectedin as the new standard of care in the second-line setting, as well as a sneak peek into the future, focusing on what's looking promising on the horizon based on findings from ongoing research efforts. The exploration of the treatment advances are framed by cases to illustrate how to integrate the new therapeutic options into practice and what factors to consider when constructing individualized treatment plans. Progress is inconsequential if it doesn't rapidly translate into practice. Are you prepared to take all the necessary steps to improve outcomes for your patients with SCLC? Upon completion of this activity, participants should be better able to: Review the role and rationale for integrating novel therapies into the SCLC treatment arsenal, Assess the safety and efficacy data evaluating established and newly approved treatment options, including transcription inhibition as a novel therapeutic approach, for patients with SCLC, Integrate approved and emerging therapies into individualized management plans for patients with SCLC taking into consideration the latest findings, current guidelines and recommendations, and patient needs and preferences.

Go online to PeerView.com/DJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What's new in the treatment of small cell lung cancer (SCLC), and how can healthcare professionals make the most of the accelerating therapeutic progress to maximize benefits for patients? For many years, SCLC was viewed as a challenging subtype of lung cancer, with limited treatment advances and poor outcomes, but recent developments have brought new options and hope for improved outcomes for these patients. This educational activity provides a grand tour through the exciting changes in the treatment arsenal for SCLC, including the impact of chemo-immunotherapy in the first-line setting and the emergence of the transcription inhibitor lurbinectedin as the new standard of care in the second-line setting, as well as a sneak peek into the future, focusing on what's looking promising on the horizon based on findings from ongoing research efforts. The exploration of the treatment advances are framed by cases to illustrate how to integrate the new therapeutic options into practice and what factors to consider when constructing individualized treatment plans. Progress is inconsequential if it doesn't rapidly translate into practice. Are you prepared to take all the necessary steps to improve outcomes for your patients with SCLC? Upon completion of this activity, participants should be better able to: Review the role and rationale for integrating novel therapies into the SCLC treatment arsenal, Assess the safety and efficacy data evaluating established and newly approved treatment options, including transcription inhibition as a novel therapeutic approach, for patients with SCLC, Integrate approved and emerging therapies into individualized management plans for patients with SCLC taking into consideration the latest findings, current guidelines and recommendations, and patient needs and preferences.

Go online to PeerView.com/DJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What's new in the treatment of small cell lung cancer (SCLC), and how can healthcare professionals make the most of the accelerating therapeutic progress to maximize benefits for patients? For many years, SCLC was viewed as a challenging subtype of lung cancer, with limited treatment advances and poor outcomes, but recent developments have brought new options and hope for improved outcomes for these patients. This educational activity provides a grand tour through the exciting changes in the treatment arsenal for SCLC, including the impact of chemo-immunotherapy in the first-line setting and the emergence of the transcription inhibitor lurbinectedin as the new standard of care in the second-line setting, as well as a sneak peek into the future, focusing on what's looking promising on the horizon based on findings from ongoing research efforts. The exploration of the treatment advances are framed by cases to illustrate how to integrate the new therapeutic options into practice and what factors to consider when constructing individualized treatment plans. Progress is inconsequential if it doesn't rapidly translate into practice. Are you prepared to take all the necessary steps to improve outcomes for your patients with SCLC? Upon completion of this activity, participants should be better able to: Review the role and rationale for integrating novel therapies into the SCLC treatment arsenal, Assess the safety and efficacy data evaluating established and newly approved treatment options, including transcription inhibition as a novel therapeutic approach, for patients with SCLC, Integrate approved and emerging therapies into individualized management plans for patients with SCLC taking into consideration the latest findings, current guidelines and recommendations, and patient needs and preferences.

On this episode, we are joined by psychiatrist, psychopharmacologist, and author, Dr. Jonathan Meyer, to talk about using antipsychotic plasma levels to assess treatment response, safety, and oral medication adherence. He is a clinical professor of psychiatry at the University of California, San Diego. He recently published a book with Dr. Stephen Stahl for clinicians to utilize called, The Clinical Use of Antipsychotic Plasma Levels: Stahl's Handbooks. Link to Blog. Link to Resource Library. 

Jeremy has a conversation with Dr. Bonni Goldstein who advised on the film Weediatrics; A Covert Medical Mission about her experience using with cannabis with children which she covers in detail in her latest book “Cannabis is Medicine: How Medical Cannabis and CBD are Healing Everything from Anxiety to Chronic Pain."  Working in San Diego, CA, she shares her experience working with cannabis compounds with children for nearly a decade.  She discusses it's use, safety and effectiveness and why we need to be able to publish research being collected to created more understanding of how to use cannabis properly to treat both adults and children.  Film:https://www.weediatricsthemovie.com/Book:https://www.amazon.com/Cannabis-Medicine-Medical-Healing-Everything-ebook/dp/B0841ZV7TMSupport the show (http://patreon.com/highwaytohealth)

Huberman Lab Podcast Notes Key Takeaways Pain and pleasure system is a scale: if you overwhelm the pleasure system, you will set yourself up for anhedonia (lack of enjoyment) and depressionDaily EPA above 1,000mg per day can be beneficial for mood and offset inflammatory pathwaysDepression interventions to change biological function: exercise, ingesting EPAs, reducing inflammation, Selective serotonin reuptake inhibitors (SSRIs)Ketamine and psilocybin take unique paths but focus on rewiring circuitry to function better in the futureThe ketogenic diet has been explored for potential relief of depressive symptoms by modulating GABBA – particularly in those who do not respond to pharmaceutical treatmentRead the full notes @ podcastnotes.orgThis episode, I explain what major depression is at the biological and psychological level and the various treatments that peer-reviewed studies have revealed can help prevent and treat depression. I explain the three major chemical systems that are altered in depression: norepinephrine, serotonin and dopamine. I discuss genetic predispositions to depression and how stress, thyroid hormone and cortisol play a role in many forms of depression. I also discuss inflammation as a common feature of many depression symptoms. I review 8 specific science-supported protocols for treating and avoiding depression, including EPA fatty acids (which have been shown to rival certain prescription treatments), how exercise protects against depression, studies of creatine, adjusting dopamine balance and more. I also discuss the results of ongoing clinical trials for ketamine and psilocybin for depression, how these compounds work and finally, I review how ketogenic diets can help in certain cases of depression, especially treatment-resistant major depression.   Thank you to our sponsors: InsideTracker - https://www.insidetracker.com/huberman Athletic Greens - https://www.athleticgreens.com/huberman Belcampo - https://www.belcampo.com/huberman -- code "huberman"   Our Patreon page: https://www.patreon.com/andrewhuberman   Supplements from Thorne: http://www.thorne.com/u/huberman   Social: Instagram - https://www.instagram.com/hubermanlab Twitter - https://twitter.com/hubermanlab Facebook - https://www.facebook.com/hubermanlab Website - https://hubermanlab.com Join Newsletter - https://hubermanlab.com/neural-network   Links: Review of EPAs for the Treatment of Depression - https://bit.ly/2Wl15ti  Review of Creatine for the Treatment of Depression - https://www.mdpi.com/520864  Recent Study on the Clinical Use of Psilocybin for Treatment of Depression - https://bit.ly/3sFSGMM    Timestamps: 00:00:00 Mood Disorders & Maintaining Mental Health (Protocol 1) 00:07:10 Sponsors 00:11:15 Major Depression 00:18:40 “Anti-Self” Confabulation 00:21:42 Autonomic (Vegetative) Symptoms of Depression 00:26:58 Norepinephrine, Dopamine & Serotonin 00:31:50 SSRIs (Prozac, Zoloft, etc.): Selective Serotonin Reuptake Inhibitors 00:37:00 Epinephrine/Motor Functions, Dopamine/Motivation & Craving, Serotonin/Emotions 00:39:33 Physical & Emotional Pain are Linked: Substance P 00:41:50 Hormones & Depression: Thyroid & Cortisol  00:46:50 Genetic Susceptibility to Depression: Impact of Stress  00:50:50 Understanding Biological Mechanism Is Key: Recipes versus Skills 00:52:50 Tools for Dealing with Depression: Logic & Implementation (Protocol 2) 00:56:25 Brain Inflammation & Mental State: Cytokines, Prostaglandins, etc. 00:59:20 Protocol 3: Essential Fatty Acids (Omega-3, EPAs: Eicosapentaenoic Acid)* 01:02:50 How EPAs Help Offset Depression: Serotonin Synthesis, Kynurenine, Quinolinic Acid 01:05:25 Protocol 4: How Exercise Offsets Depression  01:11:44 Protocol 5: Creatine Monohydrate, Forebrain Function & NMDA receptors* 01:20:30 Protocol 6*: Ketamine, PCP (*Prescription-Only), & NMDA-Receptor Function 01:33:08 Protocol 7*: Psychedelics (*In Clinical Trials) for Major Depression: Psilocybin* 01:47:00 Protocol 8: Ketogenic Diet, GABA (Gamma-Aminobutyric Acid) 01:54:50 Summary of Protocols Covered 02:00:10 Support & Additional Resources   Please note that The Huberman Lab Podcast is distinct from Dr. Huberman's teaching and research roles at Stanford University School of Medicine. The information provided in this show is not medical advice, nor should it be taken or applied as a replacement for medical advice. The Huberman Lab Podcast, its employees, guests and affiliates assume no liability for the application of the information discussed.   Title Card Photo Credit: Mike Blabac - https://www.blabacphoto.com

This episode, I explain what major depression is at the biological and psychological level and the various treatments that peer-reviewed studies have revealed can help prevent and treat depression. I explain the three major chemical systems that are altered in depression: norepinephrine, serotonin and dopamine. I discuss genetic predispositions to depression and how stress, thyroid hormone and cortisol play a role in many forms of depression. I also discuss inflammation as a common feature of many depression symptoms. I review 8 specific science-supported protocols for treating and avoiding depression, including EPA fatty acids (which have been shown to rival certain prescription treatments), how exercise protects against depression, studies of creatine, adjusting dopamine balance and more. I also discuss the results of ongoing clinical trials for ketamine and psilocybin for depression, how these compounds work and finally, I review how ketogenic diets can help in certain cases of depression, especially treatment-resistant major depression.   Thank you to our sponsors: InsideTracker - https://www.insidetracker.com/huberman Athletic Greens - https://www.athleticgreens.com/huberman Belcampo - https://www.belcampo.com/huberman -- code "huberman"   Our Patreon page: https://www.patreon.com/andrewhuberman   Supplements from Thorne: http://www.thorne.com/u/huberman   Social: Instagram - https://www.instagram.com/hubermanlab Twitter - https://twitter.com/hubermanlab Facebook - https://www.facebook.com/hubermanlab Website - https://hubermanlab.com Join Newsletter - https://hubermanlab.com/neural-network   Links: Review of EPAs for the Treatment of Depression - https://bit.ly/2Wl15ti  Review of Creatine for the Treatment of Depression - https://www.mdpi.com/520864  Recent Study on the Clinical Use of Psilocybin for Treatment of Depression - https://bit.ly/3sFSGMM    Timestamps: 00:00:00 Mood Disorders & Maintaining Mental Health (Protocol 1) 00:07:10 Sponsors 00:11:15 Major Depression 00:18:40 “Anti-Self” Confabulation 00:21:42 Autonomic (Vegetative) Symptoms of Depression 00:26:58 Norepinephrine, Dopamine & Serotonin 00:31:50 SSRIs (Prozac, Zoloft, etc.): Selective Serotonin Reuptake Inhibitors 00:37:00 Epinephrine/Motor Functions, Dopamine/Motivation & Craving, Serotonin/Emotions 00:39:33 Physical & Emotional Pain are Linked: Substance P 00:41:50 Hormones & Depression: Thyroid & Cortisol  00:46:50 Genetic Susceptibility to Depression: Impact of Stress  00:50:50 Understanding Biological Mechanism Is Key: Recipes versus Skills 00:52:50 Tools for Dealing with Depression: Logic & Implementation (Protocol 2) 00:56:25 Brain Inflammation & Mental State: Cytokines, Prostaglandins, etc. 00:59:20 Protocol 3: Essential Fatty Acids (Omega-3, EPAs: Eicosapentaenoic Acid)* 01:02:50 How EPAs Help Offset Depression: Serotonin Synthesis, Kynurenine, Quinolinic Acid 01:05:25 Protocol 4: How Exercise Offsets Depression  01:11:44 Protocol 5: Creatine Monohydrate, Forebrain Function & NMDA receptors* 01:20:30 Protocol 6*: Ketamine, PCP (*Prescription-Only), & NMDA-Receptor Function 01:33:08 Protocol 7*: Psychedelics (*In Clinical Trials) for Major Depression: Psilocybin* 01:47:00 Protocol 8: Ketogenic Diet, GABA (Gamma-Aminobutyric Acid) 01:54:50 Summary of Protocols Covered 02:00:10 Support & Additional Resources   Please note that The Huberman Lab Podcast is distinct from Dr. Huberman's teaching and research roles at Stanford University School of Medicine. The information provided in this show is not medical advice, nor should it be taken or applied as a replacement for medical advice. The Huberman Lab Podcast, its employees, guests and affiliates assume no liability for the application of the information discussed.   Title Card Photo Credit: Mike Blabac - https://www.blabacphoto.com

In this episode Michelle Bell interviews Faith Rice, Senior Research Specialist from the University of Arizona to discuss Falloposcope, a project that will potentially save lives but providing early detection for ovarian cancer.  They also discuss working in research.  To learn more about this project, click here. Published: Kelli C. Kiekens, Gabriella Romano, Dominique Galvez, Ricky Cordova, John Heusinkveld, Kenneth Hatch, William Drake, Zaynah Kmeid, Jennifer K. Barton"Re-engineering a Falloposcope Imaging System for Clinical Use", Translational biophotonics, Volume2, Issue4, November 2020, e202000011.

Granulocytes in England are unusual as they are provided as a component pooled from whole blood. Helen and Suzy discuss when their use should be considered and what to watch out for when using them

Wende Gibbs discusses Radiographics articles important for all radiologists:  skull base fractures- the new, improved Bosniak classification of renal masses and lean management principles that increase efficiency and improve patient flow in the ER. 00:00-00:32 - Introduction by Wende Gibbs, MD 00:33-07:22 -  Bosniak Classification of Cystic Renal Masses, Version 2019: A Pictorial Guide to Clinical Use. Schieda et al. RadioGraphics 2021; 41:814–828. 07:23-15:38 -  Decreasing CT Acquisition Time in the Emergency Department through Lean Management Principles. Rachh et al . RadioGraphics 2021; 41:E81–E89. 15:39-15:56 - Conclusion

In this episode, Ian Shakil discusses how Augmedix became the first company to launch a clinical application using Google Glass and a phone to convert the natural clinician-patient conversation into medical documentation. There has been an increase in adoption for natural language interface technologies for clinical applications in healthcare involving hardware, software, and data analytics. […]

In this episode, Ian Shakil discusses how Augmedix became the first company to launch a clinical application using Google Glass and a phone to convert the natural clinician-patient conversation into medical documentation. There has been an increase in adoption for natural language interface technologies for clinical applications in healthcare involving hardware, software, and data analytics. […]

Kirk Hamilton PA-C interviews Dr. Hani Saeed, DPM director of the Red Rocks Foot and Ankle Center after spending a typical busy Saturday morning treating acute and chronic pain syndromes, especially of the lower extremities, with focused and radial shock Continue reading The Clinical Use of Shock Wave Therapy in Acute and Chronic Pain Syndromes – An Interview with Dr. Hani Saeed, DPM→ The post The Clinical Use of Shock Wave Therapy in Acute and Chronic Pain Syndromes – An Interview with Dr. Hani Saeed, DPM appeared first on .

In this episode, Dr. Sabrina Green discusses the clinical aspects of phage use. We start by going back to one of the first ever uses of phage for a bacterial infection before discussing how phages are used now. Dr. Green explains a wide range of details related to clinical phage use. Topics discussed include cases today where phages are used, the safety of phages for clinical use, regulatory considerations for phage therapies, the pros and cons of phages, how specific phages are matched to specific patients, and phage affordability. Dr. Green describes potential hurdles for widespread adoption such as convincing people that viruses can be good for you. For further reading see https://www.liebertpub.com/doi/10.1089/phage.2020.0007 and https://mbio.asm.org/content/12/1/e03474-20

LEARNING OUTCOMESDiscuss the advantages of using phytomelatonin for support of health sleep patterns.Examine evidence on dosing of melatonin, including a review of the potential detrimental effects of pharmacological doses of synthetic melatonin.Review prescribing regimens for melatonin in acute vs. chronic conditions; and for a variety of applications – including for jet lag, sleep onset insomnia, early waking insomnia, and sleep maintenance issues.Explore the role of melatonin as a critical regulatory molecule within the body – looking beyond its benefits for sleep, to its antioxidant, anti-inflammatory, neuroprotective, and immunomodulatory effects.

Elaine is a Registered Nurse, Midwife and Acupuncturist based in New Zealand. She has had a keen interest in natural medicine that started as a student nurse when her mother became ill with cancer. Elaine has an interest in improving and maintaining wellness with extensive knowledge in health, nutrition, and lifestyle management. With a background in Midwifery her specialty is woman's health.In her clinic she uses acupuncture, moxa, cupping, Chinese herbal medicine, nutrition, and homeopathy, to help her patients attain optimal health, enjoy a healthy pregnancy, and have the best possible birthing experience. Elaine is currently practicing as a Midwife with a part-time caseload and as a clinical Acupuncturist. She is a member of the NZ Acupuncture Standards Association and NZ College of Midwives.CLINICAL PEARLS & RESEARCH HIGHLIGHTS FROM THIS PODCAST include:1. Review the importance of magnesium supplementation during pregnancy for preventing and managing symptoms such as cramps, mood changes, and insomnia.2. Explore the physiological roles of magnesium in preventing pre-eclampsia and pregnancy-related metabolic disturbances.3. Discuss the role of magnesium citrate in supporting a healthy labour.

In this episode, Dr. David Hanscom continues his discussion with anesthesiologist and pain specialist Dr. James Taylor. Dr. Taylor shares the work his clinics are doing to test the anti-inflammatory and pain management properties of CBD formulations. He discusses the clinical results he has achieved in helping patients reduce or eliminate their opioid use, lower their blood pressure and eliminate chronic pain. He shares his hope that one day, people will have access to specially tailored CBD formulations that will act as supplements to keep them healthy.Dr. James Taylor is a board certified anesthesiologist with a focus on pain management. He runs 7 clinics that see over 4,000 patients per month. Over the last several years, Dr. Taylor and his team have been collecting information on patients that has led to many interesting discoveries, particularly involving CBD and the pain management patient. Dr. Taylor's journey pursuing an understanding of Cannabinoid Medicine has led him to develop laboratory services for hemp farmers as well as testing on hemp related products. Dr. Taylor and his team are pursuing single molecule development using cannabinoids as the molecular backbone.

Studies finds that enzymes in cannabis may be able to treat COVID-19. Researchers at the University of Lethbridge recently released results from a study that shows the benefits of CBD as an aid in blocking the cells that enter the body from the novel coronavirus. The study is a partnership among the university, Pathway, which works to develop cannabis therapies to treat specific diseases, and cannabinoid-based oral health company Swysh Inc. The researchers at U of L conducted a study using artificial 3D models of oral, airway and intestinal tissues coupled with a limited sample of high CBD Cannabis sativa extracts, modulate ACE2 gene expression and ACE2 protein levels. The results indicated hemp extracts high in CBD may help block proteins that provide a “gateway” for COVID-19 to enter host cells. The speaker will elaborate. Speaker: Dr. Olga Kovalchuk Dr. Kovalchuk received her B. Med. (Honors, 1992) and M.D. (Stomatology, 1994) degrees at the Ivano-Frankivsk National Medical University in Ukraine. In 1994 she began a career at the Medical University and the Chernobyl Research Centre studying consequences of the Chernobyl accident, and in 1998 received a PhD (Medical Genetics). Dr. Kovalchuk conducted extensive postdoctoral training at the Friedrich Miescher Institute and in Novartis/Syngenta (Switzerland). Currently Dr. Olga Kovalchuk is a Professor and a Board of Governors' Research Chair in Epigenetics of Health and Diseases at the University of Lethbridge, Alberta. In 2008-2018 she held the Canadian Institutes for Health Research – Institute of Gender and Health (CIHR-IGH) Chairs in Gender and Health, and in Gender, Work and Health. Dr. Kovalchuk is an internationally-renowned leader and an expert in epigenetics and epigenomics of health and disease, environmental epigenomics, and radiation biology and oncology. She is studying mechanisms of disease, epigenetics, novel precision medicine approaches and novel cannabis-based disease therapies. She is a co-founder of the PathwayRx, a research and development medical cannabis company developing personalized approaches for cannabis-based treatment of cancer and age-related diseases. Date and time: Thursday, May 28, 2020 at 10 am YouTube Live link https://youtu.be/sj60GmfFht4 In order to ask questions of our speaker in the chat feature of YouTube, you must have a YouTube account and be signed in. Please do so well ahead of the scheduled start time, so you'll be ready. Go the YouTube Live link provided in this session flyer and on the top right of your browser click the “sign in” button. If you have Google or Gmail accounts, they can be used to sign in. If you don't, click “Create Account” and follow along. Once you are signed in, you can return to the live stream and use the chat feature to ask your questions of the speaker. Remember you can only participate in the chat feature while we are livestreaming. Link to SACPA's YouTube Channel: https://www.youtube.com/channel/UCFUQ5mUHv1gfmMFVr8d9dNA

Studies finds that enzymes in cannabis may be able to treat COVID-19. Researchers at the University of Lethbridge recently released results from a study that shows the benefits of CBD as an aid in blocking the cells that enter the body from the novel coronavirus. The study is a partnership among the university, Pathway, which works to develop cannabis therapies to treat specific diseases, and cannabinoid-based oral health company Swysh Inc. The researchers at U of L conducted a study using artificial 3D models of oral, airway and intestinal tissues coupled with a limited sample of high CBD Cannabis sativa extracts, modulate ACE2 gene expression and ACE2 protein levels. The results indicated hemp extracts high in CBD may help block proteins that provide a “gateway” for COVID-19 to enter host cells. The speaker will elaborate. Speaker: Dr. Olga Kovalchuk Dr. Kovalchuk received her B. Med. (Honors, 1992) and M.D. (Stomatology, 1994) degrees at the Ivano-Frankivsk National Medical University in Ukraine. In 1994 she began a career at the Medical University and the Chernobyl Research Centre studying consequences of the Chernobyl accident, and in 1998 received a PhD (Medical Genetics). Dr. Kovalchuk conducted extensive postdoctoral training at the Friedrich Miescher Institute and in Novartis/Syngenta (Switzerland). Currently Dr. Olga Kovalchuk is a Professor and a Board of Governors' Research Chair in Epigenetics of Health and Diseases at the University of Lethbridge, Alberta. In 2008-2018 she held the Canadian Institutes for Health Research – Institute of Gender and Health (CIHR-IGH) Chairs in Gender and Health, and in Gender, Work and Health. Dr. Kovalchuk is an internationally-renowned leader and an expert in epigenetics and epigenomics of health and disease, environmental epigenomics, and radiation biology and oncology. She is studying mechanisms of disease, epigenetics, novel precision medicine approaches and novel cannabis-based disease therapies. She is a co-founder of the PathwayRx, a research and development medical cannabis company developing personalized approaches for cannabis-based treatment of cancer and age-related diseases. Date and time: Thursday, May 28, 2020 at 10 am YouTube Live link https://youtu.be/sj60GmfFht4 In order to ask questions of our speaker in the chat feature of YouTube, you must have a YouTube account and be signed in. Please do so well ahead of the scheduled start time, so you'll be ready. Go the YouTube Live link provided in this session flyer and on the top right of your browser click the “sign in” button. If you have Google or Gmail accounts, they can be used to sign in. If you don't, click “Create Account” and follow along. Once you are signed in, you can return to the live stream and use the chat feature to ask your questions of the speaker. Remember you can only participate in the chat feature while we are livestreaming. Link to SACPA's YouTube Channel: https://www.youtube.com/channel/UCFUQ5mUHv1gfmMFVr8d9dNA

A presentation from Dr O'Shaughnessy featuring emerging research and cases from her practice. Introduction (00:00) Program overview: Dr Love Estrogen and Progesterone Receptors; Clinical Use of Endocrine Treatment (1:20) Case: A woman in her early 60s with ER/PR-positive, HER2-negative breast cancer (BC) who experienced intolerable arthralgias with adjuvant aromatase inhibition and was switched to tamoxifen (7:08) First-Line Endocrine Therapy for Metastatic Disease: Role of CDK4/6 Inhibitors (12:44) Case: A woman in her mid-60s with ER/PR-positive de novo metastatic BC (mBC) who received palbociclib/letrozole (12:54) Case: A woman in her mid-50s with ER/PR-positive, HER2-negative BC who developed metastatic disease after receiving 4 years of adjuvant letrozole and started treatment with ribociclib/fulvestrant (27:39) Case: A woman in her early 60s who received abemaciclib/exemestane for ER/PR-positive, HER2-negative mBC to the brain and bone (33:09) Second-Line Endocrine Therapy for Metastatic Disease: Role of mTOR Inhibitors (42:18) Case: A woman in her late 60s with ER/PR-positive, HER2-negative mBC who received exemestane/everolimus after disease progression on a CDK4/6 inhibitor (42:26) New Approaches Under Investigation (51:47) Assessing and Optimizing Treatment Adherence (59:00) Case: A woman in her early 30s with ER/PR-positive, HER2-negative BC who demonstrated poor adherence to adjuvant endocrine therapy because of weight gain (59:09) Select publications  

Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipilimumab (nivo/ipi) compared to standard doublet chemotherapy in patients with advanced NSCLC & high tumor mutational burden (TMB).